Jonas Bergh

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Jonas Bergh är professor i onkologi. Hans forskning syftar till att identifiera strategier för rätt behandlingsval till bröstcancerpatienter, baserat på riskprofiler och behandlingsprediktiva markörer.

Artiklar

Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(31):3643-3651
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
Loibl S; Jassem J; Sonnenblick A; Parlier D; Winer E; Bergh J; Gelber RD; Restuccia E; Im Y-H; Huang C-S; Dalenc F; Calvo I; Procter M; Caballero C; Clark E; Raimbault A; Mcconnell R; Monturus E; de Azambuja E; Gomez HL; Bliss J; Viale G; Bines J; Piccart M
Article: CELL REPORTS. 2024;43(10):114784
Proteome-wide CETSA reveals diverse apoptosisinducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery
Ramos AD; Liang YY; Surova O; Bacanu S; Gerault M-A; Mandal T; Ceder S; Langeback A; Osterroos A; Ward GA; Bergh J; Wiman KG; Lehmann S; Prabhu N; Loof S; Nordlund P
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2024;116(10):1654-1663
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
Dent R; Cortes J; Pusztai L; McArthur H; Kuemmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Haiderali A; Jia L; Nguyen AM; Pan W; O'Shaughnessy J; Schmid P
Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(26):3077-3082
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial
Matikas A; Moebus V; Greil R; Andersson A; Steger GG; Untch M; Fornander T; Malmstroem P; Schmatloch S; Johansson H; Hellstroem M; Brandberg Y; Gnant M; Loibl S; Foukakis T; Bergh J
Article: BRITISH JOURNAL OF CANCER. 2024;131(4):718-728
A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression
Boman C; Liu X; Eriksson Bergman L; Sun W; Tranchell C; Toli MA; Acs B; Bergh J; Foukakis T; Matikas A
Article: IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS. 2024;28(9):5312-5322
Unveiling the Power of Model-Agnostic Multiscale Analysis for Enhancing Artificial Intelligence Models in Breast Cancer Histopathology Images
Tsiknakis N; Manikis G; Tzoras E; Salgkamis D; Vidal JM; Wang K; Zaridis D; Sifakis E; Zerdes I; Bergh J; Hartman J; Acs B; Marias K; Foukakis T
Article: SCIENTIFIC REPORTS. 2024;14(1):18275
Systematic review and feasibility study on pre-analytical factors and genomic analyses on archival formalin-fixed paraffin-embedded breast cancer tissue
Salgkamis D; Sifakis EG; Agartz S; Wirta V; Hartman J; Bergh J; Foukakis T; Matikas A; Zerdes I
Article: BREAST. 2024;76:103756
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
Cardoso F; Paluch-Shimon S; Schumacher-Wulf E; Matos L; Gelmon K; Aapro MS; Bajpai J; Barrios CH; Bergh J; Bergsten-Nordstrom E; Biganzoli L; Cardoso MJ; Carey LA; Chavez-MacGregor M; Chidebe R; Cortes J; Curigliano G; Dent RA; El Saghir NS; Eniu A; Fallowfield L; Francis PA; Millan SXF; Gilchrist J; Gligorov J; Gradishar WJ; Haidinger R; Harbeck N; Hu X; Kaur R; Kiely B; Kim S-B; Koppikar S; Kuper-Hommel MJJ; Lecouvet FE; Mason G; Mertz SA; Mueller V; Myerson C; Neciosup S; Offersen BV; Ohno S; Pagani O; Partridge AH; Penault-Llorca F; Prat A; Rugo HS; Senkus E; Sledge GW; Swain SM; Thomssen C; Vorobiof DA; Vuylsteke P; Wiseman T; Xu B; Costa A; Norton L; Winer EP
Article: SCIENTIFIC REPORTS. 2024;14(1):15333
Five-year follow-up of the OptiTrain trial on concurrent resistance and high-intensity interval training during chemotherapy for patients with breast cancer
Anandavadivelan P; Mijwel S; Wiklander M; Kjoe PLM; Luijendijk M; Bergh J; Rundqvist H; Wengstrom Y
Article: CANCER DISCOVERY. 2024;14(7):1147-1153
Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally
Carmona J; Chavarria E; Donoghue K; von Gertten C; Oberrauch P; Pailler E; Scoazec G; Weijer R; Balmana J; Brana I; Brunelli C; Delaloge S; Deloger M; Delpy P; Ernberg I; Fitzgerald RC; Garralda E; Lablans M; Lehtio J; Lopez C; Fernandez M; Miceli R; Nuciforo P; Perez-Lopez R; Provenzano E; Schmidt MK; Serrano C; Steeghs N; Tamborero D; Wirta V; Baird RD; Barker K; Barlesi F; Baumann M; Bergh J; de Braud F; Fizazi K; Froehling S; Piris-Gimenez A; Seamon K; van der Heijden MS; Zwart W; Tabernero J
Article: NATURE COMMUNICATIONS. 2024;15(1):3837
Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
Wang K; Zerdes I; Johansson HJ; Sarhan D; Sun Y; Kanellis DC; Sifakis EG; Mezheyeuski A; Liu X; Loman N; Hedenfalk I; Bergh J; Bartek J; Hatschek T; Lehtio J; Matikas A; Foukakis T
Article: ANNALS OF ONCOLOGY. 2024;35(5):429-436
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 5
Pusztai L; Denkert C; O'Shaughnessy J; Cortes J; Dent R; Mcarthur H; Kuemmel S; Bergh J; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Zhu Y; Pan W; Tryfonidis K; Schmid P
Article: JOURNAL OF NUCLEAR MEDICINE. 2024;65(5):700-707
Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [ 68 Ga]Ga-ABY-025: Results from a Pilot Study
Altena R; af Buren S; Blomgren A; Karlsson E; Tzortzakakis A; Brun N; Moein MM; Jussing E; Frejd FY; Bergh J; Tran TA; Hartman J; Axelsson R
Article: BREAST CANCER RESEARCH AND TREATMENT. 2024;204(2):299-308
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
Zhu Y; Zerdes I; Matikas A; Cruz IR; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Wang K; Bergh JCS; Hatschek T; Foukakis T
Article: ECLINICALMEDICINE. 2024;67:102335
Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths - a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden
Rodriguez-Wallberg KA; Kieler H; Foukakis T; Li J; Gissler M; Oberg AS; Bergh J; Lundberg FE
Article: CELL REPORTS. 2023;42(12):113507
Report VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells
Banerjee K; Kerzel T; Bekkhus T; Ferreira SDS; Wallmann T; Wallerius M; Landwehr L-S; Agardy DA; Schauer N; Malmerfeldt A; Bergh J; Bartish M; Hartman J; Ostman A; Squadrito ML; Rolny C
Article: BMJ OPEN. 2023;13(12):e078023
ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study
Rodriguez-Wallberg KA; Nilsson HP; Bergh J; Malmros J; Ljungman P; Foukakis T; Stragliotto CL; Friman EI; Linderholm B; Valachis A; Andersson A; Harrysson S; Vennstrom L; Frisk P; Moerse H; Eloranta S
Article: THE LANCET. 2023;402(10416):1991-2003
Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials
Taylor C; Dodwell D; McGale P; Hills RK; Berry R; Bradley R; Braybrooke J; Clarke M; Gray R; Holt F; Liu Z; Pan H; Peto R; Straiton E; Bergh J; Coles C; Duane F; Hennequin C; Jones G; Kuehn T; Oliveros S; Overgaard J; Pritchard K; Suh C-O; Swain S; Whelan T; Poortmans P
Article: ANNALS OF ONCOLOGY. 2023;34(11):970-986
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.
Curigliano G; Burstein HJ; Gnant M; Loibl S; Cameron D; Regan MM; Denkert C; Poortmans P; Weber WP; Thürlimann B; St Gallen Consensus Conference Panelists 2023
Article: BREAST. 2023;70:18-24
Risk-adjusted benchmarking of long-term overall survival in patients with HER2-positive early-stage Breast cancer: A Swedish retrospective cohort study
Thurell J; Manouchehri N; Fredriksson I; Wilking U; Bergh J; Ryden L; Koppert LB; Karsten MM; Kiani NA; Hedayati E
Article: THE LANCET. 2023;401(10384):1277-1292
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
Braybrooke J; Bradley R; Gray R; Hills RK; Pan H; Peto R; Dodwell D; McGale P; Taylor C; Aihara T; Anderson S; Yothers G; Blum J; O'Shaughnessy J; Cardoso F; Chen X; Crown J; Ejlertsen B; Jensen M-B; Friedl TWP; Janni W; Harbeck N; Mamounas E; Narui K; Nitz U; Norton L; Piccart M; Robert N; Shao Z-M; Yu K-D; Slamon D; Sparano J; Watanabe T; Bergh J; Swain S; Berry R; Boddington C; Bradley R; Clarke M; Davies C; Davies L; Dodwell D; Duane F; Evans V; Gay J; Gettins L; Godwin J; Gray R; Hills RK; James S; Liu H; Liu Z; MacKinnon E; Mannu G; McGale P; McHugh T; Morris P; Nakahara M; Pan H; Peto R; Read S; Straiton E; Taylor C
Article: BREAST CANCER RESEARCH AND TREATMENT. 2023;198(3):499-508
Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records
Thoren L; Margolin S; Eliasson E; Bergh J; Lindh JD
Article: CLINICAL CANCER RESEARCH. 2023;29(3):532-540
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Gryback P; Bjohle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2023;120(1):e2209856120
Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction
Chen X; Sifakis EG; Robertson S; Neo SY; Jun S-H; Tong L; Min ATH; Lovrot J; Hellgren R; Margolin S; Bergh J; Foukakis T; Lagergren J; Lundqvist A; Ma R; Hartman J
Article: FRONTIERS IN ONCOLOGY. 2023;13:1095251
Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study
Hubbert L; Mallios P; Karlstrom P; Papakonstantinou A; Bergh J; Hedayati E
Article: NEJM EVID. 2022;1(12):EVIDoa2200162
Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.
Gnant M; Frantal S; Pfeiler G; Steger GG; Egle D; Greil R; Fitzal F; Wette V; Balic M; Haslbauer F; Melbinger-Zeinitzer E; Bjelic-Radisic V; Artner-Matuschek S; Kainberger F; Ritter M; Rinnerthaler G; Sevelda P; Bergh J; Kacerovsky-Strobl S; Suppan C; Brunner C; Deutschmann C; Gampenrieder SP; Fohler H; Jakesz R; Fesl C; Singer C
Article: ANNALS OF ONCOLOGY. 2022;33(12):1250-1268
Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Geyer CEJ; Garber JE; Gelber RD; Yothers G; Taboada M; Ross L; Rastogi P; Cui K; Arahmani A; Aktan G; Armstrong AC; Arnedos M; Balmana J; Bergh J; Bliss J; Delaloge S; Domchek SM; Eisen A; Elsafy F; Fein LE; Fielding A; Ford JM; Friedman S; Gelmon KA; Gianni L; Gnant M; Hollingsworth SJ; Im S-A; Jager A; Lakhani SR; Janni W; Linderholm B; Liu T-W; Loman N; Korde L; Loibl S; Lucas PC; Marme F; de Duenas EM; McConnell R; Phillips K-A; Piccart M; Rossi G; Schmutzler R; Senkus E; Shao Z; Sharma P; Singer CF; Spanic T; Stickeler E; Toi M; Traina TA; Viale G; Zoppoli G; Park YH; Yerushalmi R; Yang H; Pang D; Jung KH; Mailliez A; Fan Z; Tennevet I; Zhang J; Nagy T; Sonke GS; Sun Q; Parton M; Colleoni MA; Schmidt M; Brufsky AM; Razaq W; Kaufman B; Cameron D; Campbell C; Tutt ANJ; Johannsson OT
Article: LAKARTIDNINGEN. 2022;119:22093
[HER2-low breast cancer - A new entity that could expand possibilities of getting treatment].
Altena R; Tzortzakakis A; Sörensen J; Y Frejd F; Bergh J; Axelsson R
Article: JAMA ONCOLOGY. 2022;8(10):1438-1446
Relapse Rates and Disease-Specific Mortality Following Procedures for Fertility Preservation at Time of Breast Cancer Diagnosis
Marklund A; Lekberg T; Hedayati E; Liljegren A; Bergh J; Lundberg FE; Rodriguez-Wallberg KA
Article: BREAST CANCER RESEARCH AND TREATMENT. 2022;194(1):49-56
Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
Boman C; Kessler LE; Bergh J; Matikas A; Foukakis T
Article: ELIFE. 2022;11:e71562
Risk of heart disease following treatment for breast cancer - results from a population-based cohort study
Yang H; Bhoo-Pathy N; Brand JS; Hedayati E; Grassmann F; Zeng E; Bergh J; Bian W; Ludvigsson JF; Hall P; Czene K
Article: NATURE REVIEWS CLINICAL ONCOLOGY. 2022;19(3):207-215
The value of anticancer drugs - a regulatory view
Pignatti F; Wilking U; Postmus D; Wilking N; Delgado J; Bergh J
Article: THE LANCET ONCOLOGY. 2022;23(3):382-392
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
Bradley R; Braybrooke J; Gray R; Hills RK; Liu Z; Pan H; Peto R; Dodwell D; McGale P; Taylor C; Bergh J; Swain S; Francis PA; Gnant M; Perrone F; Regan MM
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2022;386(6):556-567
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kummel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier M-A; Im S-A; Ahn J-H; Gion M; Baron-Hay S; Boileau J-F; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J
Article: NATURE CANCER. 2022;3(2):251-261
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Brana I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Balmana J; Apolone G; Caldas C; Bergh J; Ernberg I; Frohling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtio J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2021;190(3):451-462
Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
Thoren L; Eriksson M; Lindh JD; Czene K; Bergh J; Eliasson E; Hall P; Margolin S
Article: NPJ BREAST CANCER. 2021;7(1):144
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
Zerdes I; Simonetti M; Matikas A; Harbers L; Acs B; Boyaci C; Zhang N; Salgkamis D; Agartz S; Moreno-Ruiz P; Bai Y; Rimm DL; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Article: ANNALS OF ONCOLOGY. 2021;32(10):1216-1235
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.
Burstein HJ; Curigliano G; Thürlimann B; Weber WP; Poortmans P; Regan MM; Senn HJ; Winer EP; Gnant M; Panelists of the St Gallen Consensus Conference
Article: CANCERS. 2021;13(18):4655
Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
Zerdes I; Karafousia V; Mezheyeuski A; Stogiannitsi M; Kuiper R; Ruiz PM; Rassidakis G; Bergh J; Hatschek T; Foukakis T; Matikas A
Article: JAMA ONCOLOGY. 2021;7(9):1360-1367
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer A Phase 2 Randomized Clinical Trial
Hatschek T; Foukakis T; Bjohle J; Lekberg T; Fredholm H; Elinder E; Bosch A; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Azavedo E; Gryback P; Hellstrom M; Johansson H; Maes C; Zerdes I; Hartman J; Brandberg Y; Bergh J
Article: THE LANCET ONCOLOGY. 2021;22(8):1139-1150
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Bergh J; Pritchard KI; Swain S; Cameron D; Albain K; Anderson S; Arriagada R; Bartlett J; Bergsten-Nordstrom E; Bliss J; Bradley R; Brain E; Braybrooke J; Carey L; Clarke M; Coleman R; Cuzick J; Davidson N; Del Mastro L; Di Leo A; Dignam J; Dodwell D; Dowsett M; Duane F; Ejlertsen B; Francis P; Gelber R; Gnant M; Goetz M; Goodwin P; Gray R; Halpin-Murphy P; Hayes D; Hill C; Jagsi R; Janni W; Liu Z; Loibl S; MacKinnon E; Mamounas E; Mannu G; Martin M; McGale P; Mukai H; Nekljudova V; Norton L; Ohashi Y; Pan H; Peto R; Piccart M; Pierce L; Poortmans P; Raina V; Rea D; Regan M; Robertson J; Rutgers E; Slamon D; Spanic T; Sparano J; Steger G; Taylor C; Tang G; Toi M; Tutt A; Viale G; Wang X; Whelan T; Wilcken N; Wolmark N
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2021;384(25):2394-2405
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ; Garber JE; Kaufman B; Viale G; Fumagalli D; Rastogi P; Gelber RD; de Azambuja E; Fielding A; Balmaña J; Domchek SM; Gelmon KA; Hollingsworth SJ; Korde LA; Linderholm B; Bandos H; Senkus E; Suga JM; Shao Z; Pippas AW; Nowecki Z; Huzarski T; Ganz PA; Lucas PC; Baker N; Loibl S; McConnell R; Piccart M; Schmutzler R; Steger GG; Costantino JP; Arahmani A; Wolmark N; McFadden E; Karantza V; Lakhani SR; Yothers G; Campbell C; Geyer CE; OlympiA Clinical Trial Steering Committee and Inve
Article: CLINICAL CANCER RESEARCH. 2021;27(12):3469-3477
High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial
Strell C; Folkvaljon D; Holmberg E; Schiza A; Thurfjell V; Karlsson P; Bergh J; Bremer T; Akslen LA; Warnberg F; Ostman A
Article: ESMO OPEN. 2021;6(2):100076
bPrognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
Matikas A; Wang K; Lagoudaki E; Acs B; Zerdes I; Hartman J; Azavedo E; Bjohle J; Carlsson L; Einbeigi Z; Hedenfalk I; Hellstrom M; Lekberg T; Loman N; Saracco A; von Wachenfeldt A; Rotstein S; Bergqvist M; Bergh J; Hatschek T; Foukakis T
Article: CANCERS. 2021;13(5):1175
CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma
Su Y; Tsagkozis P; Papakonstantinou A; Tobin NP; Gultekin O; Malmerfelt A; Ingelshed K; Neo SY; Lundquist J; Chaabane W; Nisancioglu MH; Leiss LW; Ostman A; Bergh J; Sedimbi S; Lehti K; Lundqvist A; Stragliotto CL; Haglund F; Ehnman M
Article: CANCERS. 2021;13(5):1166
Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study
Acs B; Fredriksson I; Ronnlund C; Hagerling C; Ehinger A; Kovacs A; Roge R; Bergh J; Hartman J
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2021;87(3):1243-1252
Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles
Thoren L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
Article: BREAST CANCER RESEARCH. 2021;23(1):8
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Schmid P; Sablin M-P; Bergh J; Im S-A; Lu Y-S; Martinez N; Neven P; Lee KS; Morales S; Perez-Fidalgo JA; Adamson D; Goncalves A; Prat A; Jerusalem G; Schlieker L; Espadero R-M; Bogenrieder T; Huang DC-L; Crown J; Cortes J
Article: JNCI CANCER SPECTRUM. 2021;5(1):pkaa084-
Long-Term Prognostication for 20 114 Women With Small and Node-Negative Breast Cancer (T1abN0)
Jaraj D; Hoijer J; Widman L; Ahlgren J; Arnesson L-G; Einbeigi Z; Klintman M; Patil EV; Sund M; Fredriksson I; Bergh J; Andreas P
Article: ANNALS OF ONCOLOGY. 2020;31(12):1623-1649
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso F; Paluch-Shimon S; Senkus E; Curigliano G; Aapro MS; Andre F; Barrios CH; Bergh J; Bhattacharyya GS; Biganzoli L; Boyle F; Cardoso M-J; Carey LA; Cortes J; El Saghir NS; Elzayat M; Eniu A; Fallowfield L; Francis PA; Gelmon K; Gligorov J; Haidinger R; Harbeck N; Hu X; Kaufman B; Kaur R; Kiely BE; Kim S-B; Lin NU; Mertz SA; Neciosup S; Offersen BV; Ohno S; Pagani O; Prat A; Penault-Llorca F; Rugo HS; Sledge GW; Thomssen C; Vorobiof DA; Wiseman T; Xu B; Norton L; Costa A; Winer EP
Article: SEMINARS IN MUSCULOSKELETAL RADIOLOGY. 2020;24(06):710-725
Interventional Techniques for Bone and Musculoskeletal Soft Tissue Tumors: Current Practices and Future Directions - Part II. Stabilization
Dalili D; Isaac A; Cazzato RL; Astrom G; Bergh J; Mansour R; Weber M-A; Garnon J; Gangi A
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(44):27556-27565
MNK2 governs the macrophage antiinflammatory phenotype
Bartish M; Tong D; Pan Y; Wallerius M; Liu H; Ristau J; Ferreira SDS; Wallmann T; van Hoef V; Masvidal L; Kerzel T; Joly A-L; Goncalves C; Preston SEJ; Ebrahimian T; Seitz C; Bergh J; Pietras K; Lehoux S; Naldini L; Andersson J; Squadrito ML; del RSV; Larsson O; Rolny C
Article: ESMO OPEN. 2020;5(6):e001032
PD-1 protein and gene expression as prognostic factors in early breast cancer
Matikas A; Zerdes I; Lovrot J; Sifakis E; Richard F; Sotiriou C; Rassidakis G; Bergh J; Valachis A; Foukakis T
Article: ACTA ONCOLOGICA. 2020;59(11):1382-1387
Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience
Kessler LE; Wiklander O; Hamberg E; Bergh J; Foukakis T; Matikas A
Article: ONCOGENE. 2020;39(32):5430-5440
A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels
Lundberg A; Lindstrom LS; Parker JS; Loverli E; Perou CM; Bergh J; Tobin NP
Article: ACTA ONCOLOGICA. 2020;59(7):825-832
Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1
Poikonen-Saksela P; Lindman H; Sverrisdottir A; Edlund P; Villman K; Nittby LT; Cold S; Bechmann T; Stenbygaard L; Ejlertsen B; Andersson M; Blomqvist C; Bergh J; Ahlgren J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2020;181(3):645-651
Chemotherapy use near the end-of-life in patients with metastatic breast cancer
Kessler LE; Sigfridsson J; Hatzidaki D; Bergh J; Foukakis T; Georgoulias V; Matikas A
Article: MOLECULAR ONCOLOGY. 2020;14(5):951-963
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease
Zerdes I; Sifakis EG; Matikas A; Chretien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
Article: NATURE MEDICINE. 2020;26(5):665-671
Caring for patients with cancer in the COVID-19 era
van de Haar J; Hoes LR; Coles CE; Seamon K; Frohling S; Jager D; Valenza F; de Braud F; De Petris L; Bergh J; Ernberg I; Besse B; Barlesi F; Garralda E; Piris-Gimenez A; Baumann M; Apolone G; Soria JC; Tabernero J; Caldas C; Voest EE
Article: BREAST CANCER RESEARCH AND TREATMENT. 2020;181(1):87-96
Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
Brandberg Y; Johansson H; Hellstrom M; Gnant M; Mobus V; Greil R; Foukakis T; Bergh J
Article: HUMAN REPRODUCTION. 2020;35(4):929-938
Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study
Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
Article: ONCOLOGIST. 2020;25(4):e709-e715
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Article: EUROPEAN HEART JOURNAL - QUALITY OF CARE AND CLINICAL OUTCOMES. 2020;6(2):147-155
Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based study
Hedayati E; Papakonstantinou A; Gernaat SAM; Altena R; Brand JS; Alfredsson J; Bhoo-Pathy N; Herrmann J; Linde C; Dahlstrom U; Bergh J; Hubbert L
Article: CANCER. 2020;126(6):1175-1182
Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial
Papakonstantinou A; Matikas A; Bengtsson NO; Malmstrom P; Hedayati E; Steger G; Untch M; Hubbert L; Johansson H; Hellstrom M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
Article: JOURNAL OF CLINICAL INVESTIGATION. 2020;130(3):1185-1198
CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2020;382(9):810-821
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid P; Cortes J; Pusztai L; McArthur H; Kuemmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J
Article: ACTA ONCOLOGICA. 2020;59(1):75-81
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer
Papakonstantinou A; Hedayati E; Hellstrom M; Johansson H; Gnant M; Steger G; Greil R; Untch M; Moebus V; Loibl S; Foukakis T; Bergh J; Matikas A
Article: CARDIO-ONCOLOGY. 2020;6(1):16
Approaches to management of cardiovascular morbidity in adult cancer patients - cross-sectional survey among cardio-oncology experts
Hedayati E; Papakonstantinou A; Mansson-Broberg A; Bergh J; Hubbert L; Altena R
Article: SCIENTIFIC REPORTS. 2019;9(1):19384
CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance
Langeback A; Bacanu S; Laursen H; Mout L; Seki T; Erkens-Schulze S; Ramos AD; Berggren A; Cao Y; Hartman J; van Weerden W; Bergh J; Nordlund P; Loof S
Article: CANCERS. 2019;11(10):E1479-1479
STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Zerdes I; Wallerius M; Sifakis EG; Wallmann T; Betts S; Bartish M; Tsesmetzis N; Tobin NP; Coucoravas C; Bergh J; Rassidakis GZ; Rolny C; Foukakis T
Article: EBIOMEDICINE. 2019;48:212-223
Generation of in situ sequencing based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast cancer
Svedlund J; Strell C; Qian X; Zilkens KJC; Tobin NP; Bergh J; Sieuwerts AM; Nilsson M
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2019;111(9):983-995
Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ
Strell C; Paulsson J; Jin S-B; Tobin NP; Mezheyeuski A; Roswall P; Mutgan C; Mitsios N; Johansson H; Wickberg SM; Svedlund J; Nilsson M; Hall P; Mulder J; Radisky DC; Pietras K; Bergh J; Lendahl U; Warnberg F; Ostman A
Article: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2019;200(3):348-358
Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function
Sandri BJ; Masvidal L; Murie C; Bartish M; Avdulov S; Higgins L; Markowski T; Peterson M; Bergh J; Yang P; Rolny C; Limper AH; Griffin TJ; Bitterman PB; Wendt CH; Larsson O
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2019;68(6):927-936
An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma
Tsagozis P; Augsten M; Zhang Y; Li T; Hesla A; Bergh J; Haglund F; Tobin NP; Ehnman M
Article: NATURE COMMUNICATIONS. 2019;10(1):2110
Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease
Prakash V; Carson BB; Feenstra JM; Dass RA; Sekyrova P; Hoshino A; Petersen J; Guo Y; Parks MM; Kurylo CM; Batchelder JE; Haller K; Hashimoto A; Rundqivst H; Condeelis JS; Allis CD; Drygin D; Nieto MA; Andang M; Percipalle P; Bergh J; Adameyko I; Farrants A-KO; Hartman J; Lyden D; Pietras K; Blanchard SC; Vincent CT
Article: THE LANCET. 2019;393(10179):1440-1452
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials
Boddington C; Bradley R; Braybrooke J; Burrett J; Clarke M; Davies C; Davies L; Dodwell D; Duane F; Evans V; Gettins L; Godwin J; Gray R; Hills R; James S; Liu H; Liu Z; MacKinnon E; Mannu G; McGale P; McHugh T; Morris P; Pan H; Peto R; Read S; Taylor C; Wang Y; Wang Z; Bradley R; Braybrooke J; Gray R; Bergh J; Peto R; Gray R; Bradley R; Braybrooke J; Liu Z; Peto R; Davies L; Dodwell D; McGale P; Pan H; Taylor C; Barlow W; Bliss J; Bruzzi P; Cameron D; Fountzilas G; Loibl S; Mackey J; Martin M; Del Mastro L; Moebus V; Nekljudova V; De Placido S; Swain S; Untch M; Pritchard KI; Bergh J; Norton L; Fasching P; Harbeck N; Untch M; Piedbois P; Gnant M; Steger G; Di Leo A; Dolci S; Francis P; Larsimont D; Nogaret JM; Philippson C; Piccart-Gebhart MJ; Linn S; Peer P; Tjan-Heijnen V; Vliek S; Mackey J; Martin M; Slamon D; Bartlett JMS; Bramwell VH; Chen BE; Chia SKL; Gelmon K; Goss PE; Levine MN; Parulekar W; Pater JL; Pritchard KI; Rakovitch E; Shepherd LE; Tu D; Whelan T; Berry D; Broadwater G; Cirrincione C; Muss H; Norton L; Weiss RB; Shan Y; Shao YF; Wang X; Xu B; Zhao DB; Bartelink H; Bijker N; Bogaerts J; Cardoso F; Cufer T; Julien JP; Poortmans PM; Rutgers E; van de Velde CJH; Carrasco E; Martin M; Segui MA; Blohmer JU; Costa SD; Gerber B; Jackisch C; Loibl S; Nekljudova V; von Minckwitz G; Bruzzi P; Giuliano M; De laurentiis M; De Placido S; Del Mastro L; Bamia C; Fountzilas G; Koliou G-A; Mavroudis D; A'Hern R; Bliss J; Cameron D; Ellis P; Kilburn L; Morden J; Yarnold JR; Sadoon M; Tulusan AH; Anderson S; Bass G; Costantino J; Dignam J; Fisher B; Geyer C; Mamounas EP; Paik S; Redmond C; Swain S; Wickerham L; Wolmark N; Del Mastro L; Venturini M; Bighin C; Bruzzi P; Del Mastro L; Pastorino S; Pronzato P; Sertoli MR; Barlow W; Bergh J; Foukakis T; Pritchard KI; Swain S; Cameron D; Albain K; Anderson S; Arriagada R; Barlow W; Bartlett J; Bergsten-Nordstrom E; Bliss J; Boccardo F; Bradley R; Brain E; Braybrooke J; Carey L; Clarke M; Coates A; Coleman R; Correa C; Costantino J; Cuzick J; Davidson N; Davies C; Davies L; Di Leo A; Dodwell D; Dowsett M; Duane F; Ewertz M; Forbes J; Francis P; Gelber R; Gnant M; Goldhirsch A; Goodwin P; Gray R; Hayes D; Hill C; Ingle J; Jagsi R; Janni W; Liu Z; Loibl S; MacKinnon E; Mannu G; Martin M; McGale P; Mukai H; Nekljudova V; Norton L; Ohashi Y; Paik S; Pan H; Peto R; Piccart M; Pierce L; Poortmans P; Raina V; Ravdin P; Rea D; Regan M; Robertson J; Rutgers E; Slamon D; Sparano J; Steger G; Taylor C; Tutt A; Viale G; Wang X; Whelan T; Wilcken N; Wolmark N; Wood W; Zambetti M
Article: BRITISH JOURNAL OF CANCER. 2019;120(9):913-921
Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes
Bonnefoi H; MacGrogan G; Poncet C; Iggo R; Pommeret F; Grellety T; Larsimont D; Becette V; Kerdraon O; Bibeau F; Ghnassia J-P; Picquenot J-M; Thomas J; Tille J-C; Slaets L; Bodmer A; Bergh J; Cameron D
Article: JOURNAL OF CANCER SURVIVORSHIP. 2019;13(2):244-256
High-intensity exercise during chemotherapy induces beneficial effects 12months into breast cancer survivorship
Mijwel S; Jervaeus A; Bolam KA; Norrbom J; Bergh J; Rundqvist H; Wengstrom Y
Article: BREAST CANCER RESEARCH. 2019;21(1):36
Separation of breast cancer and organ microenvironment transcriptomes in metastases
Alzubi MA; Turner TH; Olex AL; Sohal SS; Tobin NP; Recio SG; Bergh J; Hatschek T; Parker JS; Sartorius CA; Perou CM; Dozmorov MG; Harrell JC
Article: BREAST CANCER RESEARCH. 2019;21(1):34
The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours
Lundberg A; Lindstroem LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Article: ANNALS OF ONCOLOGY. 2019;30(1):109-114
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients
Matikas A; Foukakis T; Moebus V; Greil R; Bengtsson N-O; Steger GG; Untch M; Johansson H; Hellstrom M; Malmstrom P; Gnant M; Loibl S; Bergh J
Article: NATURE COMMUNICATIONS. 2018;9(1):5150
Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing
Bartoschek M; Oskolkov N; Bocci M; Lovrot J; Larsson C; Sommarin M; Madsen CD; Lindgren D; Pekar G; Karlsson G; Ringner M; Bergh J; Bjorklund A; Pietras K
Article: BREAST CANCER RESEARCH AND TREATMENT. 2018;172(3):703-712
Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34years longitudinal data from the Stockholm-Gotland cancer registry
Falato C; Taylor SK; Szulkin R; Nordblom A; Eriksson L; Sofiadis A; Fredriksson I; Hartman J; Bergh J; Foukakis T
Article: ISCIENCE. 2018;9:71-83
Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity
Wallmann T; Zhang X-M; Wallerius M; Bolin S; Joly A-L; Sobocki C; Leiss L; Jiang Y; Bergh J; Holland EC; Enger PO; Andersson J; Swartling FJ; Miletic H; Uhrbom L; Harris RA; Rolny C
Article: PHARMACOGENOMICS. 2018;19(16):1259-1268
Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients
Sim S; Bergh J; Hellstroem M; Hatschek T; Xie H
Article: ONCOGENE. 2018;37(46):6083-6095
Notch signaling promotes a HIF2α-driven hypoxic response in multiple tumor cell types
Mutvei AP; Landor SK-J; Fox R; Braune E-B; Tsoi YL; Phoon YP; Sahlgren C; Hartman J; Bergh J; Jin S; Lendahl U
Article: ONCOIMMUNOLOGY. 2018;7(9):e1466017
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
Matikas A; Lovrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Hatschek T; Erlandsson A; Foukakis T
Article: JOURNAL OF CLINICAL PATHOLOGY. 2018;71(9):787-794
Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer
Robertson S; Stalhammar G; Darai-Ramqvist E; Rantalainen M; Tobin NP; Bergh J; Hartman J
Article: INTERNATIONAL JOURNAL OF CANCER. 2018;143(5):1093-1104
Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study.
Eriksson L; Bergh J; Humphreys K; Wärnberg F; Törnberg S; Czene K
Article: ANNALS OF ONCOLOGY. 2018;29(8):1634-1657
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso F; Senkus E; Costa A; Papadopoulos E; Aapro M; Andre F; Harbeck N; Aguilar Lopez B; Barrios CH; Bergh J; Biganzoli L; Boers-Doers CB; Cardoso MJ; Carey LA; Cortes J; Curigliano G; Dieras V; El Saghir NS; Eniu A; Fallowfield L; Francis PA; Gelmon K; Johnston SRD; Kaufmann B; Koppikar S; Krop IE; Mayer M; Nakigudde G; Offersen BV; Ohno S; Pagani O; Paluch-Shimon S; Penault-Llorca F; Prat A; Rugo HS; Sledge GW; Spence D; Thomssen C; Vorobiof DA; Xu B; Norton L; Winer EP
Article: PHARMACOGENOMICS. 2018;19(13):1027-1037
Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay
Sim S; Lovrot J; Lindh JD; Bergh J; Xie H
Article: BREAST CANCER RESEARCH. 2018;20(1):64
Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors
Sjostrom M; Staaf J; Eden P; Warnberg F; Bergh J; Malmstrom P; Ferno M; Nimeus E; Fredriksson I
Article: BREAST CANCER RESEARCH AND TREATMENT. 2018;169(3):497-505
Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial
Aalders KC; Touati N; Tryfonidis K; Annonay M; Litiere S; Bergh J; Bodmer A; Cameron DA; Bonnefoi HR
Article: STATISTICAL METHODS IN MEDICAL RESEARCH. 2018;27(6):1818-1829
Feasibility of reusing time-matched controls in an overlapping cohort
Delcoigne B; Hagenbuch N; Schelin MEC; Salim A; Lindstrom LS; Bergh J; Czene K; Reilly M
Article: HISTOPATHOLOGY. 2018;72(6):974-989
Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer
Stalhammar G; Robertson S; Wedlund L; Lippert M; Rantalainen M; Bergh J; Hartman J
Article: EUROPEAN JOURNAL OF CANCER. 2018;94:79-86
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
Lindman H; Andersson M; Ahlgren J; Balslev E; Sverrisdottir A; Holmberg SB; Bengtsson NO; Jacobsen EH; Jensen AB; Hansen J; Tuxen MK; Malmberg L; Villman K; Anderson H; Ejlertsen B; Bergh J; Blomqvist C
Article: BREAST CANCER RESEARCH AND TREATMENT. 2018;169(1):93-103
Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial
Mijwel S; Backman M; Bolam KA; Olofsson E; Norrbom J; Bergh J; Sundberg CJ; Wengstrom Y; Rundqvist H
Article: JOURNAL OF CLINICAL INVESTIGATION. 2018;128(4):1355-1370
Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes
Ullah I; Karthik G-M; Alkodsi A; Kjallquist U; Stalhammar G; Lovrot J; Martinez N-F; Lagergren J; Hautaniemi S; Hartman J; Bergh J
Article: BRITISH JOURNAL OF CANCER. 2018;118(4):480-488
Immune gene expression and response to chemotherapy in advanced breast cancer
Foukakis T; Lovrot J; Matikas A; Zerdes I; Lorent J; Tobin N; Suzuki C; Brage SE; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Ferno M; Skoog L; Bergh J; Hatschek T
Article: BMC CANCER. 2018;18(1):174
Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs)
Kjallquist U; Erlandsson R; Tobin NP; Alkodsi A; Ullah I; Stalhammar G; Karlsson E; Hatschek T; Hartman J; Linnarsson S; Bergh J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2018;167(3):761-769
Safety of fertility preservation in breast cancer patients in a register-based matched cohort study
Rodriguez-Wallberg KA; Eloranta S; Krawiec K; Lissmats A; Bergh J; Liljegren A
Article: INTERNATIONAL JOURNAL OF CANCER. 2018;142(3):618-628
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
Kimbung S; Markholm I; Bjohle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellstrom M; Veerla S; Paquet E; Bendahl P-O; Ferno M; Bergh J; Loman N; Hatschek T; Hedenfalk I
Article: THE LANCET ONCOLOGY. 2018;19(1):27-39
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
Alberro JA; Ballester B; Deulofeu P; Fabregas R; Fraile M; Gubern JM; Janer J; Moral A; de Pablo JL; Penalva G; Puig P; Ramos M; Rojo R; Santesteban P; Serra C; Sola M; Solarnau L; Solsona J; Veloso E; Vidal S; Abe O; Abe R; Enomoto K; Kikuchi K; Koyama H; Masuda H; Nomura Y; Ohashi Y; Sakai K; Sugimachi K; Toi M; Tominaga T; Uchino J; Yoshida M; Coles CE; Haybittle JL; Moebus V; Leonard CF; Calais G; Garaud P; Collett V; Davies C; Delmestri A; Sayer J; Harvey VJ; Holdaway IM; Kay RG; Mason BH; Forbe JF; Franci PA; Wilcken N; Balic M; Bartsch R; Fesl C; Fitzal F; Fohler H; Gnant M; Greil R; Jakesz R; Marth C; Mlineritsch B; Pfeiler G; Singer CF; Steger GG; Stoeger H; Canney P; Yosef HMA; Focan C; Peek U; Oates GD; Powell J; Durand M; Mauriac L; Di Leo A; Dolci S; Larsimont D; Nogaret JM; Philippson C; Piccart MJ; Masood MB; Parker D; Price JJ; Lindsay MA; Mackey J; Martin M; Hupperets PSGJ; Bates T; Blamey RW; Chetty U; Ellis IO; Mallon E; Morgan DAL; Patnick J; Pinder S; Lohrisch C; Nichol A; Bartlett JMS; Bramwell VH; Chen BE; Chia SKL; Gelmon K; Goss PE; Levine MN; Parulekar W; Pater JL; Pritchard KI; Shepherd LE; Tu D; Whelan T; Berry D; Broadwater G; Cirrincione C; Muss H; Norton L; Weiss RB; Abu-Zahara HT; Karpov A; Portnoj SL; Bowden S; Brookes C; Dunn J; Fernando I; Lee M; Poole C; Rea D; Spooner D; Barrett-Lee PJ; Manse RE; Monypenny IJ; Gordon NH; Davis HL; Cuzick J; Sestak I; Lehingue Y; Romestaing P; Dubois JB; Delozier T; Griffon B; Lesec'h JM; Mustacchi G; Petruzelka L; Pribylova O; Owen JR; Meier P; Shan Y; Shao YF; Wang X; Zhao DB; Howell A; Swindell R; Albano J; de Oliveira CF; Gervasio H; Gordilho J; Ejlertsen B; Jensen M-B; Mouridsen H; Gelman RS; Harris JR; Hayes D; Henderson C; Shapiro CL; Christiansen P; Ejlertsen B; Ewertz M; Jensen MB; Mouridsen HT; Fehm T; Trampisch HJ; Dalesio O; de Vries EGE; Rodenhuis S; van Tinteren H; Comis RL; Davidson NE; Gray R; Robert N; Sledge G; Solin LJ; Sparano JA; Tormey DC; Wood W; Cameron D; Chetty U; Dixon JM; Forrest P; Jack W; Kunkler I; Rossbach J; Klijn JGM; Treurniet-Donker AD; van Putten WLJ; Rotmensz N; Veronesi U; Viale G; Bartelink H; Bijker N; Bogaerts J; Cardoso F; Cufer T; Julien JP; Poortmans PM; Rutgers E; van de Velde CJH; Cunningham MP; Huovinen R; Joensuu H; Costa A; Bonadonna G; Gianni L; Valagussa P; Goldstein LJ; Bonneterre J; Fargeot P; Fumoleau P; Kerbrat P; Lupors E; Namer M; Carrasco E; Martin M; Segui MA; Eierman W; Hilfrich J; Jonat W; Kaufmann M; Kreienberg R; Schumacher M; Bastert G; Rauschecker H; Sauer R; Sauerbrei W; Schauer A; Schumacher M; Blohmer JU; Costa SD; Eidtmann H; Gerber B; Jackisch C; Loib S; von Minckwitz G; de Schryver A; Vakaet L; Belfiglio M; Nicolucci A; Pellegrini F; Pirozzoli MC; Sacco M; Valentini M; McArdle CS; Smith DC; Stallard S; Dent DM; Gudgeon CA; Hacking A; Murray E; Panieri E; Werner ID; De Salvo GL; Del Bianco P; Zavagno G; Leone B; Vallejo CT; Zwenger A; Galligioni E; Lopez M; Erazo A; Medina JY; Horiguchi J; Takei H; Fentiman IS; Hayward JL; Rubens RD; Skilton D; Scheurlen H; Kaufmann M; Sohn HC; Untch M; Dafni U; Markopoulos C; Bamia C; Fountzilas G; Koliou G-A; Manousou K; Mavroudis D; Klefstrom P; Blomqvist C; Saarto T; Gallen M; Canavese G; Tinterri C; Margreiter R; de Lafontan B; Mihura J; Roche H; Asselain B; Salmon RJ; Vilcoq JR; Brain E; de La Lande B; Mouret-Fourme E; Andre F; Arriagada R; Delaloge S; Hill C; Koscienly S; Michiels S; Rubino C; A'Hern R; Bliss J; Ellis P; Kilburn L; Yarnold JR; Martin M; Benraadt J; Kooi M; van de Velde AO; van Dongen JA; Vermorken JB; Castiglione M; Coates A; Colleoni M; Collins J; Forbes J; Gelbe RD; Goldhirsch A; Lindtner J; Price KN; Regan MM; Rudenstam CM; Senn HJ; Thuerlimann B; Bliss JM; Chilvers CED; Coombes RC; Hall E; Marty M; Buyse M; Possinger K; Schmid P; Untch M; Wallwiener D; Foster L; George WD; Stewart HJ; Stroner P; Borovik R; Hayat H; Inbar MJ; Peretz T; Robinson E; Camerini T; Formelli F; Martelli G; Di Mauro MG; Valagussa P; Perrone F; Amadori D; Martoni A; Pannuti F; Camisa R; Musolino A; Passalacqua R; Iwata H; Shien T; Abe O; Ikeda T; Inokuchi K; Kikuchi K; Sawa K; Sonoo H; Sadoon M; Tulusan AH; Kohno N; Miyashita M; Takao S; Ahn J-H; Jung KH; Korzeniowski S; Skolyszewski J; Ogawa M; Yamashita J; Bastiaannet E; Liefers GJ; van de Velde CJH; Christiaens R; Neven P; Paridaens R; Van den Bogaert W; Gazet JC; Corcoran N; Deshpande N; di Martino L; Douglas P; Hacking A; Host H; Lindtner A; Notter G; Bryant AJS; Ewing GH; Firth LA; Krushen-Kosloski JL; Nissen-Meyer R; Anderson H; Killander F; Malmstrom P; Ryden L; Arnesson L-G; Carstense J; Dufmats M; Fohlin H; Nordenskjold B; Soderberg M; Sundqvist M; Carpenter TJ; Murray N; Royle GT; Simmonds PD; Albain K; Barlow W; Crowley J; Hayes D; Gralow J; Hortobagyi G; Livingston R; Martino S; Osborne CK; Ravdin PM; Bergh J; Bondesso T; Celebiogl F; Dahlberg K; Fornander T; Fredriksson I; Frisell J; Goransson E; Iiristo M; Johansson U; Lenner E; Lofgren L; Nikolaidis P; Perbeck L; Rotstein S; Sandelin K; Skoog L; Svane G; af Trampe E; Wadstrom C; Janni W; Castiglione M; Goldhirsch A; Maibach R; Senn HJ; Thurlimann B; Bartlett JMS; Bastiaannet E; Hadji P; Hozumi J; Rea D; van de Velde CJH; Holli K; Rouhento K; Safra T; Brenner H; Hercbergs A; Yoshimoto M; Paterson AHG; Pritchard KI; Fyles A; Meakin JW; Panzarella T; Pritchard KI; Bahi J; Delaloge S; Lemonnier J; Martin AL; Reid M; Spittle M; Bishop H; Bundred NJ; Cuzick J; Ellis IO; Fentiman IS; Forbes JF; Forsyth S; George WS; Pinder SE; Sestak I; Deutsch GP; Gray R; Kwong DLW; Pai VR; Peto R; Senanayake F; Boccardo F; Rubagotti A; Baum M; Forsyth S; Hackshaw A; Houghton J; Ledermann J; Monson K; Tobias JS; Carlomagno C; De Laurentiis M; De Placido S; Schem C; Williams L; Bell R; Cameron D; Coleman RE; Dodwell D; Hinsley S; Marshall HC; Hayes D; Pierce LJ; Basso SMM; Lumachi F; Solomayer E; Coleman RE; Horsman JM; Lester J; Winter MC; Buzdar AU; Hsu L; Love RR; Ahlgren J; Garmo H; Holmberg L; Lindman H; Warnberg F; Asmar L; Jones SE; Aft R; Gluz O; Harbeck N; Liedtke C; Nitz U; Litton A; Wallgren A; Karlsson P; Linderholm BK; Chlebowski RT; Caffier H; Brufsky AM; Coleman RE; Llombart HA
Article: CLINICAL CANCER RESEARCH. 2017;23(24):7512-7520
Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
Lundberg A; Lindstrom LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Article: CLINICAL CANCER RESEARCH. 2017;23(23):7225-7231
PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients
Tobin NP; Lundberg A; Lindstrom LS; Harrell JC; Foukakis T; Carlsson L; Einbeigi Z; Linderholm BK; Loman N; Malmberg M; Ferno M; Czene K; Perou CM; Bergh J; Hatschek T
Article: CLINICAL BREAST CANCER. 2017;17(8):585-594.e4
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
Baselga J; Zamagni C; Gomez P; Bermejo B; Nagai SE; Melichar B; Chan A; Mangel L; Bergh J; Costa F; Gomez HL; Gradishar WJ; Hudis CA; Rapoport BL; Roche H; Maeda P; Huang L; Meinhardt G; Zhang J; Schwartzberg LS
Article: BMC CANCER. 2017;17(1):802
Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling
Karthik G-M; Rantalainen M; Stalhammar G; Lovrot J; Ullah I; Alkodsi A; Ma R; Wedlund L; Lindberg J; Frisell J; Bergh J; Hartman J
Article: CANCER CELL. 2017;32(5):669-683.e5
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Palazon A; Tyrakis PA; Macias D; Velica P; Rundqvist H; Fitzpatrick S; Vojnovic N; Phan AT; Loman N; Hedenfalk I; Hatschek T; Lovrot J; Foukakis T; Goldrath AW; Bergh J; Johnson RS
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2017;377(19):1836-1846
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan H; Gray R; Braybrooke J; Davies C; Taylor C; McGale P; Peto R; Pritchard KI; Bergh J; Dowsett M; Hayes DF
Article: EUROPEAN JOURNAL OF CANCER. 2017;84:278-289
Breast cancer in young women and prognosis: How important are proliferation markers?
Fredholm H; Magnusson K; Lindstrom LS; Tobin NP; Lindman H; Bergh J; Holmberg L; Ponten F; Frisell J; Fredriksson I
Article: EUROPEAN JOURNAL OF CANCER. 2017;84:325-334
Societal challenges of precision medicine: Bringing order to chaos
Salgado R; Moore H; Martens JWM; Lively T; Malik S; McDermott U; Michiels S; Moscow JA; Tejpar S; McKee T; Lacombe D
Article: ANNALS OF ONCOLOGY. 2017;28(8):1700-1712
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Curigliano G; Burstein HJ; Winer EP; Gnant M; Dubsky P; Loibl S; Colleoni M; Regan MM; Piccart-Gebhart M; Senn H-J; Thurlimann B; Andre F; Baselga J; Bergh J; Bonnefoi H; Brucker SY; Cardoso F; Carey L; Ciruelos E; Cuzick J; Denkert C; Di Leo A; Ejlertsen B; Francis P; Galimberti V; Garber J; Gulluoglu B; Goodwin P; Harbeck N; Hayes DF; Huang C-S; Huober J; Khaled H; Jassem J; Jiang Z; Karlsson P; Morrow M; Orecchia R; Osborne KC; Pagani O; Partridge AH; Pritchard K; Ro J; Rutgers EJT; Sedlmayer F; Semiglazov V; Shao Z; Smith I; Toi M; Tutt A; Viale G; Watanabe T; Whelan TJ; Xu B
Article: JOURNAL OF CLINICAL ONCOLOGY. 2017;35(15):1641-1649
Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials
Taylor C; Correa C; Duane FK; Aznar MC; Anderson SJ; Bergh J; Dodwell D; Ewertz M; Gray R; Jagsi R; Pierce L; Pritchard KI; Swain S; Wang Z; Wang Y; Whelan T; Peto R; McGale P
Article: CLINICAL CANCER RESEARCH. 2017;23(10):2584-2592
Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes
Li J; Ivansson E; Klevebring D; Tobin NP; Lindstrom LS; Holm J; Prochazka G; Cristando C; Palmgren J; Tornberg S; Humphreys K; Hartman J; Frisell J; Rantalainen M; Lindberg J; Hall P; Bergh J; Gronberg H; Czene K
Article: SUPPORTIVE CARE IN CANCER. 2017;25(5):1423-1429
A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment
Browall M; Brandberg Y; Nasic S; Rydberg P; Bergh J; Ryden A; Xie H; Eriksson I; Wengstrom Y
Article: SCIENTIFIC REPORTS. 2017;7(1):1089
Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer
Kruger K; Wik E; Knutsvik G; Nalwoga H; Klingen TA; Arnes JB; Chen Y; Mannelqvist M; Dimitrakopoulou K; Stefansson IM; Birkeland E; Aas T; Tobin NP; Jonassen I; Bergh J; Foulkes WD; Akslen LA
Article: ACTA RADIOLOGICA. 2017;58(4):394-402
Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy
Saracco A; Szabo BK; Tanczos E; Bergh J; Hatschek T
Article: LAKARTIDNINGEN. 2017;114:EEIS
[Chemotherapy and targeted drugs to reinforce each other].
Foukakis T; Bergh J
Article: BREAST. 2017;31:244-259
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
Cardoso F; Costa A; Senkus E; Aapro M; Andre F; Barrios CH; Bergh J; Bhattacharyya G; Biganzoli L; Cardoso MJ; Carey L; Corneliussen-James D; Curigliano G; Dieras V; El Saghir N; Eniu A; Fallowfield L; Fenech D; Francis P; Gelmon K; Gennari A; Harbeck N; Hudis C; Kaufman B; Krop I; Mayer M; Meijer H; Mertz S; Ohno S; Pagani O; Papadopoulos E; Peccatori F; Pernault-Llorca F; Piccart MJ; Pierga JY; Rugo H; Shockney L; Sledge G; Swain S; Thomssen C; Tutt A; Vorobiof D; Xu B; Norton L; Winer E
Article: CANCER. 2017;123(3):468-475
Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study.
Brand JS; Hedayati E; Bhoo-Pathy N; Bergh J; Hall P; Humphreys K; Ludvigsson JF; Czene K
Article: ANNALS OF ONCOLOGY. 2017;28(2):208-217
Research needs in breast cancer
Cardoso F; Harbeck N; Barrios CH; Bergh J; Cortes J; El Saghir N; Francis PA; Hudis CA; Ohno S; Partridge AH; Sledge GW; Smith IE; Gelmon KA
Article: THE JOURNAL OF PATHOLOGY: CLINICAL RESEARCH. 2017;3(1):38-43
High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
Paulsson J; Ryden L; Strell C; Frings O; Tobin NP; Fornander T; Bergh J; Landberg G; Stal O; Ostman A
Article: SCIENTIFIC REPORTS. 2016;6:38037
Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers.
Rantalainen M; Klevebring D; Lindberg J; Ivansson E; Rosin G; Kis L; Celebioglu F; Fredriksson I; Czene K; Frisell J; Hartman J; Bergh J; Grönberg H
Article: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA). 2016;316(18):1888-1896
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer A Randomized Clinical Trial
Foukakis T; von Minckwitz G; Bengtsson N-O; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellstrom M; Johansson H; Anderson H; Malmstrom P; Gnant M; Greil R; Mobus V; Bergh J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2016;160(1):131-143
Long-term outcome in young women with breast cancer: a population-based study
Fredholm H; Magnusson K; Lindstrom LS; Garmo H; Falt SE; Lindman H; Bergh J; Holmberg L; Ponten F; Frisell J; Fredriksson I
Article: CLINICAL CANCER RESEARCH. 2016;22(21):5249-5255
Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients.
Brand JS; Hedayati E; Humphreys K; Ludvigsson JF; Johansson ALV; Bergh J; Hall P; Czene K
Article: CANCER RESEARCH. 2016;76(11):3166-3178
Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages
Wallerius M; Wallmann T; Bartish M; Ostling J; Mezheyeuski A; Tobin NP; Nygren E; Pangigadde P; Pellegrini P; Squadrito ML; Ponten F; Hartman J; Bergh J; DeMilito A; De Palma M; Ostman A; Andersson J; Rolny C
Article: JOURNAL OF INFECTION. 2016;72(6):650-658
Infection-related hospitalizations in breast cancer patients: Risk and impact on prognosis.
Brand JS; Colzani E; Johansson ALV; Giesecke J; Clements M; Bergh J; Hall P; Czene K
Article: CLINICAL CANCER RESEARCH. 2016;22(10):2417-2426
An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Tobin NP; Wennmalm K; Lindstrom LS; Foukakis T; He L; Genove G; Ostman A; Landberg G; Betsholtz C; Bergh J
Article: BRITISH JOURNAL OF CANCER. 2016;114(10):1117-1124
Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer
Sjoberg E; Augsten M; Bergh J; Jirstrom K; Ostman A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(14):1573-1U58
Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?
Papakonstantinou A; Foukakis T; Rodriguez-Wallberg KA; Bergh J
Article: MODERN PATHOLOGY. 2016;29(4):318-329
Digital image analysis outperforms manual biomarker assessment in breast cancer
Stalhammar G; Martinez NF; Lippert M; Tobin NP; Molholm I; Kis L; Rosin G; Rantalainen M; Pedersen L; Bergh J; Grunkin M; Hartman J
Article: MOLECULAR ONCOLOGY. 2016;10(4):517-525
Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse
Falato C; Tobin NP; Lorent J; Lindstrom LS; Bergh J; Foukakis T
Article: FRONTIERS IN GENETICS. 2016;7:214
MICADo - Looking for Mutations in Targeted PacBio Cancer Data: An Alignment-Free Method
Rudewicz J; Soueidan H; Uricaru R; Bonnefoi H; Iggo R; Bergh J; Nikolski M
Article: ONCOTARGET. 2015;6(32):33306-33318
Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications
Kimbung S; Kovacs A; Danielsson A; Bendahl P-O; Lovgren K; Stolt MF; Tobin NP; Lindstrom L; Bergh J; Einbeigi Z; Ferno M; Hatschek T; Hedenfalk I
Article: CANCER LETTERS. 2015;367(1):76-87
mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells
Karthik G-M; Ma R; Lovrot J; Kis LL; Lindh C; Blomquist L; Fredriksson I; Bergh J; Hartman J
Article: THE LANCET. 2015;386(10001):1353-1361
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Coleman R; Powles T; Paterson A; Gnant M; Anderson S; Diel I; Gralow J; von Minckwitz G; Moebus V; Bergh J; Pritchard KI; Bliss J; Cameron D; Evans V; Pan H; Peto R; Bradley R; Gray R; Bartsch R; Dubsky P; Fesl C; Fohler H; Greil R; Jakesz R; Lang A; Luschin-Ebengreuth G; Marth C; Mlineritsch B; Samonigg H; Singer CF; Steger GG; Stoeger H; Olivotto I; Ragaz J; Christiansen P; Ejlertsen B; Ewertz M; Jensen M-B; Moller S; Mouridsen HT; Eiermann W; Hilfrich J; Jonat W; Kaufmann M; Kreienberg R; Schumacher M; Blohmer JU; Costa SD; Eidtmann H; Gerber B; Jackisch C; Loibl S; von Minckwitz G; Dafni U; Markopoulos C; Blomqvist C; Saarto T; Ahn J-H; Jung KH; Perrone F; Anderson S; Bass G; Brown A; Bryant J; Costantino J; Dignam J; Fisher B; Geyer C; Mamounas EP; Paik S; Redmond C; Swain S; Wickerham L; Wolmark N; Perez E; Ingle JN; Suman VJ; Hadji P; A'Hern R; Dowsett M; Makris A; Parton M; Pennert K; Powles TJ; Smith IE; Yarnold JR; Clack G; Van Poznak C; Safra T; Bell R; Cameron D; Coleman RE; Dodwell D; Hinsley S; Marshall HC; Solomayer E; Fehm T; Coleman RE; Lester J; Winter MC; Horsman JM; Aft R; Brufsky AM; Coleman R; Llombart HA
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2015;107(10):djv209
Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells
Hong J; Tobin NP; Rundqvist H; Li T; Lavergne M; Garcia-Ibanez Y; Qin H; Paulsson J; Zeitelhofer M; Adzemovic MZ; Nilsson I; Roswall P; Hartman J; Johnson RS; Ostman A; Bergh J; Poljakovic M; Genove G
Article: ACTA ONCOLOGICA. 2015;54(7):1040-1048
Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment
Ekholm M; Grabau D; Bendahl P-O; Bergh J; Elmberger G; Olsson H; Russo L; Viale G; Ferno M
Article: ANNALS OF ONCOLOGY. 2015;26(8):1533-1546
Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Coates AS; Winer EP; Goldhirsch A; Gelber RD; Gnant M; Piccart-Gebhart M; Thuerlimann B; Senn H-J
Article: MOLECULAR ONCOLOGY. 2015;9(7):1384-1391
Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer
Foukakis T; Lovrot J; Sandqvist P; Xie H; Lindstrom LS; Giorgetti C; Jacobsson H; Hedayati E; Bergh J
Article: THE LANCET. 2015;386(9992):433-443
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF
Article: CANCER RESEARCH. 2015;75(12):2445-2456
Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer
Cunha SI; Bocci M; Lovrot J; Eleftheriou N; Roswall P; Cordero E; Lindstrom L; Bartoschek M; Haller BK; Pearsall RS; Mulivor AW; Kumar R; Larsson C; Bergh J; Pietras K
Article: ACTA ONCOLOGICA. 2015;54(4):522-529
A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden
Kessler L; Falato C; Margolin S; Bergh J; Foukakis T
Article: ANNALS OF ONCOLOGY. 2015;26(3):517-522
Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers.
Li J; Holm J; Bergh J; Eriksson M; Darabi H; Lindström LS; Törnberg S; Hall P; Czene K
Article: ONCOLOGIST. 2015;20(2):196-201
The European Medicines Agency Approval of Axitinib (Inlyta) for the Treatment of Advanced Renal Cell Carcinoma After Failure of Prior TreatmentWith Sunitinib or a Cytokine: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersboll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
Article: CLINICAL PROTEOMICS. 2015;12(1):8
Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer
Johansson HJ; Sanchez BC; Forshed J; Stal O; Fohlin H; Lewensohn R; Hall P; Bergh J; Lehtio J; Linderholm BK
Article: ANNALS OF ONCOLOGY. 2015;26(1):81-88
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
Tobin NP; Harrell JC; Lövrot J; Egyhazi Brage S; Frostvik Stolt M; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Walz T; Fernö M; Perou CM; Bergh J; Hatschek T; Lindström LS
Article: MOLECULAR ONCOLOGY. 2014;8(8):1690-1702
miR-206 inhibits cell migration through direct targeting of the actin-binding protein Coronin 1C in triple-negative breast cancer
Wang J; Tsouko E; Jonsson P; Bergh J; Hartman J; Aydogdu E; Williams C
Article: EUROPEAN JOURNAL OF CANCER. 2014;50(17):2916-2924
Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology
Karlsson E; Appelgren J; Solterbeck A; Bergenheim M; Alvariza V; Bergh J
Article: ANNALS OF ONCOLOGY. 2014;25(10):1871-1888
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso F; Costa A; Norton L; Senkus E; Aapro M; Andre F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL; Cardoso MJ; Cufer T; El Saghir N; Fallowfield L; Fenech D; Francis P; Gelmon K; Giordano SH; Gligorov J; Goldhirsch A; Harbeck N; Houssami N; Hudis C; Kaufman B; Krop I; Kyriakides S; Lin UN; Mayer M; Merjaver SD; Nordstrom EB; Pagani O; Partridge A; Penault-Llorca F; Piccart MJ; Rugo H; Sledge G; Thomssen C; van't Veer L; Vorobiof D; Vrieling C; West N; Xu B; Winer E
Article: BREAST. 2014;23(5):489-502
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso F; Costa A; Norton L; Senkus E; Aapro M; Andre F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL; Cardoso MJ; Cufer T; El Saghir N; Fallowfield L; Fenech D; Francis P; Gelmon K; Giordano SH; Gligorov J; Goldhirsch A; Harbeck N; Houssami N; Hudis C; Kaufman B; Krop I; Kyriakides S; Lin UN; Mayer M; Merjaver SD; Nordstrom EB; Pagani O; Partridge A; Penault-Llorca F; Piccart MJ; Rugo H; Sledge G; Thomssen C; van't Veer L; Vorobiof D; Vrieling C; West N; Xu B; Winer E
Article: BREAST CANCER RESEARCH AND TREATMENT. 2014;147(2):407-414
Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer
Falato C; Lorent J; Tani E; Karlsson E; Wright PK; Bergh J; Foukakis T
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2014;74(3):549-558
Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide
von Stedingk H; Xie H; Hatschek T; Foukakis T; Ryden A; Bergh J; Rydberg P
Article: BRITISH JOURNAL OF CANCER. 2014;111(5):918-926
Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis
Rosin G; de Boniface J; Karthik GM; Frisell J; Bergh J; Hartman J
Article: THE LANCET. 2014;384(9938):164-172
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CEJ; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
Article: BREAST CANCER RESEARCH. 2014;16(4):R72
Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo
Klevebring D; Rosin G; Ma R; Lindberg J; Czene K; Kere J; Fredriksson I; Bergh J; Hartman J
Article: LABORATORY INVESTIGATION. 2014;94(7):796-805
Superficial scrapings from breast tumors is a source for biobanking and research purposes
Ma R; Fredriksson I; Karthik G-M; Winn G; Darai-Ramqvist E; Bergh J; Hartman J
Article: ONCOLOGIST. 2014;19(7):766-773
The European Medicines Agency Review of Pertuzumab for the Treatment of Adult Patients With HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Boix-Perales H; Borregaard J; Jensen KB; Ersboll J; Galluzzo S; Giuliani R; Ciceroni C; Melchiorri D; Salmonson T; Bergh J; Schellens JH; Pignatti F
Article: THE LANCET. 2014;383(9935):2127-2135
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
McGale P; Taylor C; Correa C; Cutter D; Duane F; Ewertz M; Gray R; Mannu G; Peto R; Whelan T; Wang Y; Wang Z; Darby S
Article: HISTOPATHOLOGY. 2014;64(7):971-980
Low concordance of biomarkers in histopathological and cytological material from breast cancer
Stalhammar G; Rosin G; Fredriksson I; Bergh J; Hartman J
Article: ANNALS OF ONCOLOGY. 2014;25(6):1128-1136
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
Bonnefoi H; Litiere S; Piccart M; MacGrogan G; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Moldovan C; Bodmer A; Zaman K; Cufer T; Campone M; Luporsi E; Malmstrom P; Werutsky G; Bogaerts J; Bergh J; Cameron DA
Article: MOLECULAR ONCOLOGY. 2014;8(3):741-752
Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients
Tobin NP; Lindstrom LS; Carlson JW; Bjohle J; Bergh J; Wennmalm K
Article: ONCOLOGIST. 2014;19(3):217-224
A Catalyst for Change: The European Cancer Patient's Bill of Rights
Lawler M; Le Chevalier T; Murphy BJJ; Banks I; Conte P; De Lorenzo F; Meunier F; Pinedo HM; Selby P; Armand J-P; Barbacid M; Barzach M; Bergh J; Bode G; Cameron DA; de Braud F; de Gramont A; Diehl V; Diler S; Erdem S; Fitzpatrick JM; Geissler J; Hollywood D; Hojgaard L; Horgan D; Jassem J; Johnson PW; Kapitein P; Kelly J; Kloezen S; La Vecchia C; Loewenberg B; Oliver K; Sullivan R; Tabernero J; Van de Velde CJ; Wilking N; Wilson R; Zielinski C; Zur Hausen H; Johnston PG
Article: EUROPEAN JOURNAL OF CANCER. 2014;50(3):517-524
Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirstrom K; Bergh J; Warnberg F
Article: BREAST. 2013;22(6):1142-1147
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
Linderholm BK; Lidbrink E; Tallroth E; Einbeigi Z; Svensson H; von Wachenfeldt A; Norberg B; Carlsson L; Olsson ME; Bergh J; Wilking N; Hatschek T
Article: JOURNAL OF PATHOLOGY. 2013;231(4):441-448
Validation of a yeast functional assay for p53 mutations using clonal sequencing
Iggo R; Rudewicz J; Monceau E; Sevenet N; Bergh J; Sjoblom T; Bonnefoi H
Article: BMC CANCER. 2013;13:473
Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies
Milosevic J; Klinge J; Borg A-L; Foukakis T; Bergh J; Tobin NP
Article: ANNALS OF ONCOLOGY. 2013;24(9):2206-2223
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Goldhirsch A; Winer EP; Coates AS; Gelber RD; Piccart-Gebhart M; Thuerlimann B; Senn H-J
Article: AMERICAN JOURNAL OF PATHOLOGY. 2013;182(6):2037-2047
Prognostic Significance in Breast Cancer of a Gene Signature Capturing Stromal PDGF Signaling
Frings O; Augsten M; Tobin NP; Carlson J; Paulsson J; Pena C; Olsson E; Veerla S; Bergh J; Ostman A; Sonnhammer ELL
Article: BREAST CANCER RESEARCH AND TREATMENT. 2013;139(3):751-758
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
Bjohle J; Bergqvist J; Gronowitz JS; Johansson H; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Soderberg M; Sundquist M; Walz TM; Ferno M; Bergh J; Hatschek T
Article: GENOME BIOLOGY. 2013;14(4):R34
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
Nagalla S; Chou JW; Willingham MC; Ruiz J; Vaughn JP; Dubey P; Lash TL; Hamilton-Dutoit SJ; Bergh J; Sotiriou C; Black MA; Miller LD
Article: BRITISH JOURNAL OF CANCER. 2013;108(5):1195-1208
Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study
Walters S; Maringe C; Butler J; Rachet B; Barrett-Lee P; Bergh J; Boyages J; Christiansen P; Lee M; Waernberg F; Allemani C; Engholm G; Fornander T; Gjerstorff ML; Johannesen TB; Lawrence G; McGahan CE; Middleton R; Steward J; Tracey E; Turner D; Richards MA; Coleman MP
Article: MEDICAL ONCOLOGY. 2012;29(5):3431-3439
A retrospective study of SBRT of metastases in patients with primary sarcoma
Stragliotto CL; Karlsson K; Lax I; Rutkowska E; Bergh J; Strander H; Blomgren H; Friesland S
Article: ANNALS OF ONCOLOGY. 2012;23(11):2866-2873
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
Prat A; Parker JS; Fan C; Cheang MCU; Miller LD; Bergh J; Chia SKL; Bernard PS; Nielsen TO; Ellis MJ; Carey LA; Perou CM
Article: CLINICAL CANCER RESEARCH. 2012;18(18):5134-5143
Validation of a Radiosensitivity Molecular Signature in Breast Cancer
Eschrich SA; Fulp WJ; Pawitan Y; Foekens JA; Smid M; Martens JWM; Echevarria M; Kamath V; Lee J-H; Harris EE; Bergh J; Torres-Roca JF
Article: CURRENT BREAST CANCER REPORTS. 2012;4(3):171-173
Analysis of Cyclin D1 in Breast Cancer: A Call to Arms.
Tobin NP; Bergh J
Article: ANNALS OF ONCOLOGY. 2012;23:349-353
When to order a biopsy to characterise a metastatic relapse in breast cancer
Foukakis T; Astrom G; Lindstrom L; Hatschek T; Bergh J
Article: BREAST. 2012;21(4):507-513
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer
Bergh J; Mariani G; Cardoso F; Liljegren A; Awada A; Vigano L; Huang X; Verkh L; Kern KA; Giorgetti C; Gianni L
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(21):2601-2608
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Lindstrom LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
Article: BRITISH JOURNAL OF CANCER. 2012;107(1):18-23
Mammographic density and molecular subtypes of breast cancer
Eriksson L; Hall P; Czene K; Silva IDS; McCormack V; Bergh J; Bjohle J; Ploner A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(16):1919-1925
FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
Bergh J; Jonsson P-E; Lidbrink EK; Trudeau M; Eiermann W; Brattstrom D; Lindemann JPO; Wiklund F; Henriksson R
Article: BREAST. 2012;21(3):242-252
1st International consensus guidelines for advanced breast cancer (ABC 1)
Cardoso F; Costa A; Norton L; Cameron D; Cufer T; Fallowfield L; Francis P; Gligorov J; Kyriakides S; Lin N; Pagani O; Senkus E; Thomssen C; Aapro M; Bergh J; Di Leo A; El Saghir N; Ganz PA; Gelmon K; Goldhirsch A; Harbeck N; Houssami N; Hudis C; Kaufman B; Leadbeater M; Mayer M; Rodger A; Rugo H; Sacchini V; Sledge G; van't Veer L; Viale G; Krop I; Winer E
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(9):921-929
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
Bergh J; Bondarenko IM; Lichinitser MR; Liljegren A; Greil R; Voytko NL; Makhson AN; Cortes J; Lortholary A; Bischoff J; Chan A; Delaloge S; Huang X; Kern KA; Giorgetti C
Article: BMC CANCER. 2012;12:79
The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer
Rosin G; Hannelius U; Lindstrom L; Hall P; Bergh J; Hartman J; Kere J
Article: NATURE REVIEWS CLINICAL ONCOLOGY. 2012;9(4):236-243
Hurdles in anticancer drug development from a regulatory perspective
Jonsson B; Bergh J
Article: THE LANCET. 2012;379(9814):432-444
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
Albain K; Anderson S; Arriagada R; Barlow W; Bergh J; Bliss J; Buyse M; Cameron D; Carrasco E; Clarke M; Correa C; Coates A; Collins R; Costantino J; Cutter D; Cuzick J; Darby S; Davidson N; Davies C; Davies K; Delmestri A; Di Leo A; Dowsett M; Elphinstone P; Evans V; Ewertz M; Gelber R; Gettins L; Geyer C; Goldhirsch A; Godwin J; Gray R; Gregory C; Hayes D; Hill C; Ingle J; Jakesz R; James S; Kaufmann M; Kerr A; MacKinnon E; McGale P; McHugh T; Norton L; Ohashi Y; Paik S; Pan HC; Perez E; Peto R; Piccart M; Pierce L; Pritchard K; Pruneri G; Raina V; Ravdin P; Robertson J; Rutgers E; Shao YF; Swain S; Taylor C; Valagussa P; Viale G; Whelan T; Winer E; Wang Y; Wood W
Article: BREAST CANCER RESEARCH AND TREATMENT. 2012;131(3):939-947
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
Hatschek T; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Lindh B; Loman N; Malmberg M; Rotstein S; Soderberg M; Sundquist M; Walz TM; Hellstrom M; Svensson H; Astrom G; Brandberg Y; Carstensen J; Ferno M; Bergh J
Article: AMERICAN SOCIETY OF CLINICAL ONCOLOGY EDUCATIONAL BOOK / ASCO. AMERICAN SOCIETY OF CLINICAL ONCOLOGY. MEETING. 2012;:71-79
Update of the oxford overview: new insight and perspectives in the era of personalized medicine.
Pritchard KI; Bergh J; Burstein HJ
Article: THE LANCET. 2011;378(9804):1707-1716
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
Article: CANCER RESEARCH. 2011;71(21):6728-6737
An Iron Regulatory Gene Signature Predicts Outcome in Breast Cancer
Miller LD; Coffman LG; Chou JW; Black MA; Bergh J; D'Agostino RJ; Torti SV; Torti FM
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;130(2):553-560
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden
Foukakis T; Fornander T; Lekberg T; Hellborg H; Adolfsson J; Bergh J
Article: THE LANCET. 2011;378(9793):771-784
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Davies C; Godwin J; Gray R; Clarke M; Darby S; McGale P; Wang YC; Peto R; Pan HC; Cutter D; Taylor C; Ingle J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(24):3214-3223
High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials
Berry DA; Ueno NT; Johnson MM; Lei X; Caputo J; Rodenhuis S; Peters WP; Leonard RC; Barlow WE; Tallman MS; Bergh J; Nitz UA; Gianni AM; Basser RL; Zander AR; Coombes RC; Roche H; Tokuda Y; de Vries EGE; Hortobagyi GN; Crown JP; Pedrazzoli P; Bregni M; Demirer T
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;128(3):755-763
Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer
Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
Article: BMC CANCER. 2011;11:306
A simple method for assigning genomic grade to individual breast tumours
Wennmalm K; Bergh J
Article: THE LANCET ONCOLOGY. 2011;12(6):527-539
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
Bonnefoi H; Piccart M; Bogaerts J; Mauriac L; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Blot E; Zaman K; Cufer T; Lortholary A; Lidbrink E; Andre S; Litiere S; Dal Lago L; Becette V; Cameron DA; Bergh J; Iggo R
Article: GENOME RESEARCH. 2011;21(5):665-675
Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes
Hillmer AM; Yao F; Inaki K; Lee WH; Ariyaratne PN; Teo ASM; Woo XY; Zhang Z; Zhao H; Chen JP; Zhu F; So JBY; Salto-Tellez M; Poh WT; Zawack KFB; Nagarajan N; Gao S; Li G; Kumar V; Lim HPJ; Sia YY; Chan CS; Leong ST; Neo SC; Choi PSD; Thoreau H; Tan PBO; Shahab A; Ruan X; Bergh J; Hall P; Cacheux-Rataboul V; Wei C-L; Yeoh KG; Sung W-K; Bourque G; Liu ET; Ruan Y
Article: GENOME RESEARCH. 2011;21(5):676-687
Transcriptional consequences of genomic structural aberrations in breast cancer
Inaki K; Hillmer AM; Ukil L; Yao F; Woo XY; Vardy LA; Zawack KFB; Lee CWH; Ariyaratne PN; Chan YS; Desai KV; Bergh J; Hall P; Putti TC; Ong WL; Shahab A; Cacheux-Rataboul V; Karuturi RKM; Sung W-K; Ruan X; Bourque G; Ruan Y; Liu ET
Article: ACTA ONCOLOGICA. 2011;50(3):338-343
Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels
Iiristo M; Wiklund T; Wilking N; Bergh J; Brandberg Y
Article: ACTA ONCOLOGICA. 2011;50(3):329-337
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1
Edlund P; Ahlgren J; Bjerre K; Andersson M; Bergh J; Mouridsen H; Holmberg SB; Bengtsson N-O; Jakobsen E; Moller S; Lindman H; Blomqvist C
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;126(2):421-430
Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen
Khoshnoud MR; Lofdahl B; Fohlin H; Fornander T; Stal O; Skoog L; Bergh J; Nordenskjold B
Article: CLINICAL EPIDEMIOLOGY. 2011;3:103-106
Breast cancer associated with primary hyperparathyroidism: a nested case control study.
Norenstedt S; Granath F; Ekbom A; Bergh J; Lambe M; Adolfsson J; Warnberg F; Zedenius J; Nilsson I-L
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(3):264-271
Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study
Andersson M; Lidbrink E; Bjerre K; Wist E; Enevoldsen K; Jensen AB; Karlsson P; Tange UB; Sorensen PG; Moller S; Bergh J; Langkjer ST
Article: THE LANCET. 2011;377(9760):127-138
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data
Coleman MP; Forman D; Bryant H; Butler J; Rachet B; Maringe C; Nur U; Tracey E; Coory M; Hatcher J; McGahan CE; Turner D; Marrett L; Gjerstorff ML; Johannesen TB; Adolfsson J; Lambe M; Lawrence G; Meechan D; Morris EJ; Middleton R; Steward J; Richards MA
Article: ACTA ONCOLOGICA. 2011;50(1):35-41
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
Margolin S; Bengtsson N-O; Carlsson L; Edlund P; Hellstrom M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmstrom P; Skold DP; Soderberg M; Villman K; Bergh J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;125(2):447-455
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;125(2):553-561
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
Wilking U; Karlsson E; Skoog L; Hatschek T; Lidbrink E; Elmberger G; Johansson H; Lindstrom L; Bergh J
Article: LAKARTIDNINGEN. 2010;107(40):2376-2377
[Great risk of future problems for Swedish cancer care].
Bergh J; Wilking N
Article: ACTA ONCOLOGICA. 2010;49(6):844-850
Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden
Wilking U; Jonsson B; Wilking N; Bergh J
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2010;8:53
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
Norell H; Poschke I; Charo J; Wei WZ; Erskine C; Piechocki MP; Knutson KL; Bergh J; Lidbrink E; Kiessling R
Article: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(12):2114-2122
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
Korde LA; Zujewski JA; Kamin L; Giordano S; Domchek S; Anderson WF; Bartlett JMS; Gelmon K; Nahleh Z; Bergh J; Cutuli B; Pruneri G; McCaskill-Stevens W; Gralow J; Hortobagyi G; Cardoso F
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2010;25(5):735-741
The impact of RNA standardization and heterogeneous gene expression on the results of cDNA array of human breast carcinoma
Khoshnoud R; He Q; Sylvan M; Khoshnoud A; Ivarsson M; Fornander T; Bergh J; Frisell J; Rutqvist L-E; Skog S
Article: BREAST CANCER RESEARCH. 2010;12(6):R105
Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer
Akhoondi S; Lindstrom L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grander D; Sangfelt O
Article: MEDICAL ONCOLOGY. 2009;26(4):480-490
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Article: CLIMACTERIC. 2009;12(6):478-489
Hormone replacement therapy after breast cancer: attitudes of women eligible in a randomized trial
Wallberg B; von Schoultz E; Bolund C; Bergh J; Wilking N
Article: EUROPEAN JOURNAL OF CANCER. 2009;45(18):3198-3204
The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 study
Rosendahl M; Ahlgren J; Andersen J; Bergh J; Blomquist C; Lidbrink E; Lindman H; Mouridsen H; Bjerre K; Andersson M
Article: BRITISH JOURNAL OF CANCER. 2009;101(6):902-907
Impact of tumour size on axillary involvement and distant dissemination in breast cancer
Koscielny S; Arriagada R; Adolfsson J; Fornander T; Bergh J
Article: BREAST. 2009;18(4):259-262
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer
Liljegren A; Bergh J; Castany R
Article: AMERICAN JOURNAL OF PATHOLOGY. 2009;175(1):334-341
Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer
Paulsson J; Sjoblom T; Micke P; Ponten F; Landberg G; Heldin C-H; Bergh J; Brennan DJ; Jirstrom K; Ostman A
Article: NATURE MEDICINE. 2009;15(1):68-74
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Farmer P; Bonnefoi H; Anderle P; Cameron D; Wirapati P; Becette V; Andre S; Piccart M; Campone M; Brain E; MacGrogan G; Petit T; Jassem J; Bibeau F; Blot E; Bogaerts J; Aguet M; Bergh J; Iggo R; Delorenzi M
Article: BREAST CANCER RESEARCH. 2009;11(Suppl 3):S16
Breast tumour stroma is a prognostic indicator and target for therapy
Howell A; Landberg G; Bergh J
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2008;105(47):18490-18495
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer
Weichselbaum RR; Ishwaran H; Yoon T; Nuyten DSA; Baker SW; Khodarev N; Su AW; Shaikh AY; Roach P; Kreike B; Roizman B; Bergh J; Pawitan Y; de Vijver MJV; Minn AJ
Article: ONCOTARGETS AND THERAPY. 2008;1:67-78
Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling
Maruwge W; D'Arcy P; Folin A; Brnjic S; Wejde J; Davis A; Erlandsson F; Bergh J; Brodin B
Article: CELL. 2008;134(1):62-73
Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression
Godar S; Ince TA; Bell GW; Feldser D; Donaher JL; Bergh J; Liu A; Miu K; Watnick RS; Reinhardt F; McAllister SS; Jacks T; Weinberg RA
Article: ANNALS OF ONCOLOGY. 2008;19(3):487-495
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
Lidgren M; Joensson B; Rehnberg C; Willking N; Bergh J
Article: THE LANCET. 2008;371(9606):29-40
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials
Clarke M; Coates AS; Darby SC; Davies C; Gelber RD; Godwin I; Goldhirsch A; Gray R; Peto R; Pritchard KI; Wood WC
Article: ACTA ONCOLOGICA. 2008;47(4):740-746
Bisphosphonate treatment in primary breast cancer:: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
Kristensen B; Ejlertsen B; Mouridsen HT; Jensen M-B; Andersen J; Bjerregaard B; Cold S; Edlund P; Ewertz M; Kamby C; Lindman H; Nordenskjold B; Bergh J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2007;25(27):4210-4216
Incidence and prognosis of synchronous and Metachronous bilateral breast cancer
Hartman M; Czene K; Reilly M; Adolfsson J; Bergh J; Adami H-O; Dickman PW; Hall P
Article: MEDICAL ONCOLOGY. 2007;24(3):267-272
Erythropoietin therapy and cancer related anaemia:: updated Swedish recommendations
Ahlqvist-Rastad J; Albertsson M; Bergh J; Birgegard G; Johansson P; Jonsson B; Kjellen E; Pahlman S; Zackrisson B; Osterborg A
Article: CANCER NURSING. 2007;30(3):E10-E19
Individual psychosocial support for breast cancer patients: a randomized study of nurse versus psychologist interventions and standard care.
Arving C; Sjödén P-O; Bergh J; Hellbom M; Johansson B; Glimelius B; Brandberg Y
Article: EUROPEAN JOURNAL OF CANCER. 2007;43(7):1153-1160
A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer
Villman K; Ohd JF; Lidbrink E; Malmberg L; Lindh B; Blomqvist C; Nordgren H; Bergh J; Bergstrom D; Ahlgren J
Article: ANNALS OF ONCOLOGY. 2007;18(5):845-850
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome
Bergqvist J; Ohd JF; Smeds J; Klaar S; Isola J; Nordgren H; Elmberger GP; Hellborg H; Bjohle J; Borg A-L; Skoog L; Bergh J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2007;25(10):1239-1246
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
Loi S; Haibe-Kains B; Desmedt C; Lallemand F; Tutt AM; Gillet C; Ellis P; Harris A; Bergh J; Foekens JA; Klijn JGM; Larsimont D; Buyse M; Bontempi G; Delorenzi M; Piccart MJ; Sotiriou C
Article: ANNALS OF ONCOLOGY. 2007;18(4):694-700
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
Wilking N; Lidbrink E; Wiklund T; Erikstein B; Lindman H; Malmstroem P; Kellokumpu-Lehtinen P; Bengtsson N-O; Soederlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Bergh J
Article: EUROPEAN JOURNAL OF CANCER. 2007;43(5):877-884
Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer
Ejlertsen B; Mouridsen HT; Jensen M-B; Andersen J; Cold S; Edlund P; Ewertz M; Jensen BB; Kamby C; Nordenskjold B; Bergh J
Article: THE LANCET. 2007;369(9555):29-36
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Smith I; Procter M; D Gelber R; Guillaume S; Feyereislova A; Dowsett M; Goldhirsch A; Untch M; Mariani G; Baselga J; Kaufmann M; Cameron D; Bell R; Bergh J; Coleman R; Wardley A; Harbeck N; Lopez RI; Mallmann P; Gelmon K; Wilcken N; Wist E; Sanchez Rovira P; Piccart-Gebhart M
Article: ACTA ONCOLOGICA. 2007;46(2):165-171
Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer
Lindman H; Astrom G; Ahlgren J; Villman K; Blomqvist C; Nygren P; Bergh J
Article: ACTA ONCOLOGICA. 2007;46(2):146-152
Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: Is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - results from a randomized study
Kellokumpu-Lehtinen P; Bergh J; Salminen E; Wiklund T; Lehtinen S; Aronen P; Sintonen H
Article: BREAST CANCER RESEARCH. 2007;9(2):R25
Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer
Lin C-Y; Stroem A; Kong SL; Kietz S; Thomsen JS; Tee JBS; Vega VB; Miller LD; Smeds J; Bergh J; Gustafsson J-A; Liu ET
Article: GENES CHROMOSOMES AND CANCER. 2007;46(1):87-97
Gene expression in 16q is associated with survival and differs between Sorlie breast cancer subtypes
Wennmalm K; Calza S; Ploner A; Hall P; Bjoehle J; Klaar S; Smeds J; Pawitan Y; Bergh J
Article: CANCER RESEARCH. 2006;66(21):10292-10301
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer
Ivshina AV; George J; Senko O; Mow B; Putti TC; Smeds J; Lindahl T; Pawitan Y; Hall P; Nordgren H; Wong JEL; Liu ET; Bergh J; Kuznetsov VA; Miller LD
Article: JOURNAL OF CLINICAL ONCOLOGY. 2006;24(31):4956-4962
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: From a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer
Ejlertsen B; Mouridsen HT; Jensen M-B; Bengtsson N-O; Bergh J; Cold S; Edlund P; Ewertz M; de Graaf PW; Kamby C; Nielsen DL
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2006;98(17):1183-1192
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
Buyse M; Loi S; van't Veer L; Viale G; Delorenzi M; Glas AM; d'Assignies MS; Bergh J; Lidereau R; Ellis P; Harris A; Bogaerts J; Therasse P; Floore A; Amakrane M; Piette F; Rutgers E; Sotiriou C; Cardoso F; Piccart MJ
Article: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 2006;15(9):1630-1635
Genomic instability and prognosis in breast carcinomas
Kronenwett U; Ploner A; Zetterberg A; Bergh J; Hall P; Auer G; Pawitan Y
Article: PATIENT EDUCATION AND COUNSELING. 2006;62(2):235-243
Satisfaction, utilisation and perceived benefit of individual psychosocial support for breast cancer patients -: A randomised study of nurse versus psychologist interventions
Arving C; Sjoden P-O; Lindstrom AT; Wasteson E; Glimelius B; Brandberg Y
Article: CLINICAL CANCER RESEARCH. 2006;12(14):4185-4191
Basoluminal carcinoma:: A new biologically and prognostically distinct entity between basal and luminal breast cancer
Laakso M; Tanner M; Nilsson J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmstroem P; Wilking N; Bergh J; Isola J
Article: CANCER RESEARCH. 2006;66(14):7334-7340
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome
Frasor J; Chang EC; Komm B; Lin C-Y; Vega VB; Liu ET; Miller LD; Smeds J; Bergh J; Katzenellenbogen BS
Article: BMC MEDICINE. 2006;4:16
Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis:: a cohort study
Hall P; Ploner A; Bjohle J; Huang F; Lin C-Y; Liu ET; Miller LD; Nordgren H; Pawitan Y; Shaw P; Skoog L; Smeds J; Wedren S; Ohd J; Bergh J
Article: BIOINFORMATICS. 2006;22(12):1477-1485
Identifying gene expression changes in breast cancer that distinguish early and late relapse among uncured patients
Broet P; Kuznetsov VA; Bergh J; Liu ET; Miller LD
Article: JOURNAL OF CLINICAL ONCOLOGY. 2006;24(16):2428-2436
Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:: Scandinavian Breast Group Trial 9401
Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmstrom P; Wilking N; Nilsson J; Bergh J
Article: INTERNATIONAL JOURNAL OF CANCER. 2006;118(11):2877-2881
Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
Drageset V; Nesland JM; Erikstein B; Skovlund E; Sommer H; Anker G; Wist E; Lundgren S; Bergh J; Kvalheim G
Article: EUROPEAN JOURNAL OF CANCER. 2006;42(8):1104-1112
Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen
Bergqvist J; Elmberger G; Ohd J; Linderholm B; Bjohle J; Hellborg H; Nordgren H; Borg A-L; Skoog L; Bergh J
Article: NUCLEAR MEDICINE COMMUNICATIONS. 2006;27(4):347-352
Different methods for the detection of small changes in uptake between single-photon emission computed tomography (SPECT) examinations:: ^99mTc-sestamibi in chemotherapy for breast tumours
Jacobsson H; Wilczek B; Bergh J; von Schoultz E; Eriksson E; Larsson SA
Article: CLINICAL CANCER RESEARCH. 2006;12(4):1157-1167
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
Olivier M; Langerod A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Borresen-Dale AL
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2006;98(4):262-272
Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis
Sotiriou C; Wirapati P; Loi S; Harris A; Fox S; Smeds J; Nordgren H; Farmer P; Praz V; Haibe-Kains B; Desmedt C; Larsimont D; Cardoso F; Peterse H; Nuyten D; Buyse M; Van de Vijver MJ; Bergh J; Piccart MT; Delorenzi M
Article: METHODS IN MOLECULAR MEDICINE. 2006;120:389-401
Sequencing of the tumor suppressor gene TP 53.
Linderholm B; Norberg T; Bergh J
Article: ACTA ONCOLOGICA. 2006;45(5):550-558
Improvements in patient satisfaction at an outpatient clinic for patients with breast cancer
Bergenmar M; Nylen U; Lidbrink E; Bergh J; Brandberg Y
Article: BREAST CANCER RESEARCH. 2006;8(4):R34
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients
Calza S; Hall P; Auer G; Bjohle J; Klaar S; Kronenwett U; T Liu E; Miller L; Ploner A; Smeds J; Bergh J; Pawitan Y
Article: THE LANCET. 2005;366(9503):2087-2106
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
Abe O; Abe R; Enomoto K; Kikuchi K; Koyama H; Masuda H; Nomura Y; Sakai K; Sugimachi K; Tominaga T; Uchino J; Yoshida M; Haybittle JL; Davies C; Harvey VJ; Holdaway TM; Kay RG; Mason BH; Forbes JF; Wilcken N; Gnant M; Jakesz R; Ploner M; Yosef HMA; Focan C; Lobelle JP; Peek U; Oates GD; Powell J; Durand M; Mauriac L; Di Leo A; Dolci S; Piccart MJ; Masood MB; Parker D; Price JJ; Hupperets PSGJ; Jackson S; Ragaz J; Berry D; Broadwater G; Cirrincione C; Muss H; Norton L; Weiss RB; Abu-Zahra HT; Portnoj SM; Baum M; Cuzick J; Houghton J; Riley D; Mansel RE; Gordon NH; Davis HL; Beatrice A; Mihura J; Naja A; Lehingue Y; Romestaing P; Dubois JB; Delozier T; Lesec'h JM; Rambert P; Petruzelka L; Pribylova O; Owen JR; Harbeck N; Jänicke F; Meisner G; Meier P; Howell A; Ribeiro GC; Swindell R; Burrett J; Clarke M; Collins R; Darby S; Davies C; Elphinstone P; Evans V; Godwin J; Gray R; Harwood C; Hicks C; Jackson D; James S; MacKinnon E; McGale P; McHugh T; Mead G; Morris P; Oulds J; Peto R; Taylor C; Wang Y; Albano J; de Oliveira CF; Gervásio H; Gordilho J; Johansen H; Mouridsen HT; Gelman RS; Harris JR; Henderson IC; Shapiro CL; Christiansen P; Ejlertsen B; Mouridsen HT; Moller S; Overgaard M; Carstensen B; Palshof T; Trampisch HJ; Dalesio O; de Vries EGE; Rodenhuis S; van Tinteren H; Comis RL; Davidson NE; Gray R; Robert N; Sledge G; Tormey DC; Wood W; Cameron D; Chetty U; Forrest P; Jack W; Rossbach J; Klijn JGM; Treurniet-Donker AD; van Putten WLJ; Costa A; Veronesi U; Bartelink H; Duchateau L; Legrand C; Sylvester R; Catalano R; Creech RH; Bonneterre J; Fargeot P; Fumoleau P; Kerbrat P; Namer M; Jonat W; Kaufman M; Schumacher M; von Minckwitz G; Bastert G; Rauschecker H; Sauer R; Sauerbrei W; Schauer A; Schumacher M; de Schyrver A; Vakaet L; Belfiglio M; Nicolucci A; Pellegrini F; Sacco M; Valentini M; McArdle CS; Smith DC; Galligioni E; Boccardo F; Rubagotti A; Dent DM; Gudgeon CA; Hacking A; Erazo A; Medina JY; Izuo M; Morishita Y; Takei H; Fentiman IS; Hayward JL; Rubens RD; Skilton D; Scheurlen H; Kaufmann M; von Fournier D; Dafni U; Fountzilas G; Klefstrom P; Blomqvist C; Saarto T; Magreiter R; Asselain B; Salmon RJ; Vilcoq JR; Arriagada R; Hill C; Laplanche A; Lê MG; Spielmann M; Bruzzi P; Montanaro E; Rosso R; Sertoli MR; Venturini M; Amadori D; Benraadt J; Kooi M; van de Velde AO; van Dongen JA; Vermorken JB; Castiglione M; Cavalli F; Coates A; Collins J; Forbes J; Gelber RD; Goldhirsch A; Lindtner J; Price KN; Rudenstam CM; Senn HJ; Bliss JM; Chilvers CED; Coombes RC; Hall E; Marty M; Borovik R; Brufman G; Hayat H; Robinson E; Wigler N; Bonadonna G; Camerini T; De Palo G; Del Vecchio M; Formelli F; Valagussa P; Martoni A; Pannuti F; Cocconi G; Colozza A; Camisa R; Aogi K; Takashima S; Abe O; Ikeda T; Inokuchi K; Kikuchi K; Sawa K; Sonoo H; Korzeniowski S; Skolyszewski J; Ogawa M; Yamashita J; Bonte J; Christiaens R; Paridaens R; Van den Bogaert W; Martin P; Romain S; Hakes T; Hudis CA; Norton L; Wittes R; Giokas G; Kondylis D; Lissaios B; de la Huerta R; Sainz MG; Altemus R; Cowan K; Danforth D; Lichter A; Lippman M; O'Shaughnessy J; Pierce LJ; Steinberg S; Venzon D; Zujewski JA; Paradiso A; De Lena M; Schittulli F; Myles JD; Pater JL; Pritchard KI; Whelan T; Nomura Y; Anderson S; Bass G; Brown A; Bryant J; Costantino J; Dignam J; Fisher B; Redmond C; Wieand S; Wolmark N; Baum M; Jackson IM; Palmer MK; Ingle JN; Suman VJ; Bengtsson NO; Jonsson H; Larsson LG; Lythgoe JP; Swindell R; Kissin M; Erikstein B; Hannisdal E; Jacobsen AB; Varhaug JE; Erikstein B; Gundersen S; Hauer-Jensen M; Host H; Jacobsen AB; Nissen-Meyer R; Blamey RW; Mitchell AK; Morgan DAL; Robertson JFR; Di Palma M; Mathé G; Misset JL; Clark RM; Levine M; Pritchard KI; Whelan T; Morimoto K; Sawa K; Takatsuka Y; Crossley E; Harris A; Talbot D; Taylor M; Cocconi G; di Blasio B; Ivanov V; Semiglazov V; Brockschmidt J; Cooper MR; Ueo H; Falkson CI; A'Hern R; Ashley S; Powles TJ; Smith IE; Yarnold JR; Gazet JC; Cocoran N; Deshpande N; de Martino L; Douglas P; Hacking A; Host H; Lindtner A; Notter G; Bryant AJS; Ewing GH; Firth LA; Krushen-Kosloski JL; Nissen-Meyer R; Foster L; George WD; Stewart HJ; Stroner P; Malmström P; Möller TR; Rydén S; Tengrup I; Tennvall-Nittby L; Carstenssen J; Dufmats M; Hatschek T; Nordenskjöld B; Söderberg M; Carpenter JT; Albain K; Crowley J; Green S; Martino S; Osborne CK; Ravdin PM; Glas U; Johansson U; Rutqvist LE; Singnomklao T; Wallgren A; Castiglione M; Goldhirsch A; Maibach R; Senn HJ; Thürlimann B; Brenner H; Hercbergs A; Yoshimoto M; DeBoer G; Paterson AHG; Pritchard KI; Meakin JW; Panzarella T; Pritchard KI; Shan Y; Shao YF; Wang X; Zhao DB; Bahi J; Reid M; Spittle M; Deutsch GP; Senanayake F; Kwong DLW; Bianco AR; Carlomagno C; De Laurentiis M; De Placido S; Buzdar AU; Smith T; Bergh J; Holmberg L; Liljegren G; Nilsson J; Seifert M; Sevelda P; Zielinsky CC; Buchanan RB; Cross M; Royle GT; Dunn JA; Hills RK; Lee M; Morrison JM; Spooner D; Litton A; Chlebowski RT; Caffier H
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2005;97(21):1609-1610
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy:: Results from a randomized trial
Nordenskjöld B; Rosell J; Rutqvist LE; Malmström PO; Bergh J; Bengtsson NO; Hatschek T; Wallgren A; Carstensen J
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2005;102(38):13550-13555
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
Miller LD; Smeds J; George J; Vega VB; Vergara L; Ploner A; Pawitan Y; Hall P; Klaar S; Liu ET; Bergh J
Article: ONCOGENE. 2005;24(29):4660-4671
Identification of molecular apocrine breast tumours by microarray analysis
Farmer P; Bonnefoi H; Becette V; Tubiana-Hulin M; Fumoleau P; Larsimont D; MacGrogan G; Bergh J; Cameron D; Goldstein D; Duss S; Nicoulaz AL; Brisken C; Fiche M; Delorenzi M; Iggo R
Article: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(18):4179-4191
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide
Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
Article: THE LANCET ONCOLOGY. 2005;6(6):377-382
Genetic implications of bilateral breast cancer: A population-based cohort study
Hartman M; Czene K; Reilly M; Bergh J; Lagiou P; Trichopoulos D; Adami HO; Hall P
Article: THE LANCET. 2005;365(9472):1687-1717
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
Abe O; Abe R; Enomoto K; Kikuchi K; Koyama H; Masuda H; Nomura Y; Sakai K; Sugimachi K; Tominaga T; Uchino J; Yoshida M; Haybittle JL; Davies C; Harvey VJ; Holdaway TM; Kay RG; Mason BH; Forbes JF; Wilcken N; Gnant M; Jakesz R; Ploner M; Yosef HMA; Focan C; Lobelle JP; Peek U; Oates GD; Powell J; Durand M; Mauriac L; Di Leo A; Dolci S; Piccart MJ; Masood MB; Parker D; Price JJ; Hupperets PSGJ; Jackson S; Ragaz J; Berry D; Broadwater G; Cirrincione C; Muss H; Norton L; Weiss RB; Abu-Zahra HT; Portnoj SM; Baum M; Cuzick J; Houghton J; Riley D; Gordon NH; Davis HL; Beatrice A; Mihura J; Naja A; Lehingue Y; Romestaing P; Dubois JB; Delozier T; Mace-Lesec'h J; Rambert P; Andrysek O; Barkmanova J; Owen JR; Meier P; Howell A; Ribeiro GC; Swindell R; Alison R; Boreham J; Clarke M; Collins R; Darby S; Davies C; Elphinstone P; Evans V; Godwin J; Gray R; Harwood C; Hicks C; James S; MacKinnon E; McGale P; McHugh T; Mead G; Peto R; Wang Y; Albano J; de Oliveira CF; Gervásio H; Gordilho J; Johansen H; Mouridsen HT; Gelman RS; Harris JR; Henderson IC; Shapiro CL; Andersen KW; Axelsson CK; Blichert-Toft M; Moller S; Mouridsen HT; Overgaard J; Overgaard M; Rose C; Cartensen B; Palshof T; Trampisch HJ; Dalesio O; de Vries EGE; Rodenhuis S; van Tinteren H; Comis RL; Davidson NE; Gray R; Robert N; Sledge G; Tormey DC; Wood W; Cameron D; Chetty U; Forrest P; Jack W; Rossbach J; Klijn JGM; Treurniet-Donker AD; van Putten WLJ; Costa A; Veronesi U; Bartelink H; Duchateau L; Legrand C; Sylvester R; van der Hage JA; van de Velde CJH; Cunningham MP; Catalano R; Creech RH; Bonneterre J; Fargeot P; Fumoleau P; Kerbrat P; Namer M; Jonat W; Kaufmann M; Schumacher M; von Minckwitz G; Bastert G; Rauschecker H; Sauer R; Sauerbrei W; Schauer A; Schumacher M; de Schryver A; Vakaet L; Belfiglio M; Nicolucci A; Pellegrini F; Sacco M; Valentini M; McArdle CS; Smith DC; Galligioni E; Boccardo F; Rubagotti A; Dent DM; Gudgeon CA; Hacking A; Erazo A; Medina JY; Izuo M; Morishita Y; Takei H; Fentiman IS; Hayward JL; Rubens RD; Skilton D; Graeff H; Jänicke F; Meisner C; Scheurlen H; Kaufmann M; von Fournier D; Dafni U; Fountzilas G; Klefstrom P; Blomqvist C; Saarto T; Margreiter R; Asselain B; Salmon RJ; Vilcoq JR; Arriagada R; Hill C; Laplanche A; Lê MG; Spielmann M; Bruzzi P; Montanaro E; Rosso R; Sertoli MR; Venturini M; Amadori D; Benraadt J; Kooi M; van de Velde AO; van Dongen JA; Vermorken JB; Castiglione M; Cavalli F; Coates A; Collins J; Forbes J; Gelber RD; Goldhirsch A; Lindtner J; Price KN; Rudenstam CM; Senn HJ; Bliss JM; Chilvers CED; Coombes RC; Hall E; Marty M; Borovik R; Brufman G; Hayat H; Robinson E; Wigler N; Bonadonna G; Camerini T; De Palo G; Del Vecchio M; Formelli F; Valagussa P; Martoni A; Pannuti F; Cocconi G; Colozza A; Camisa R; Aogi K; Takashima S; Abe O; Ikeda T; Inokuchi K; Kikuchi K; Sawa K; Sonoo H; Korzeniowski S; Skolyszewski J; Ogawa M; Yamashita J; Bonte J; Christiaens R; Paridaens R; Van den Boegart W; Martin P; Romain S; Hakes T; Hudis CA; Norton L; Wittes R; Giokas G; Kondylis D; Lissaios B; de la Huerta R; Sainz MG; Altemus R; Cowan K; Danforth D; Lichter A; Lippman M; O'Shaughnessy J; Pierce LJ; Steinberg S; Venzon D; Zujewski J; Paradiso A; De Lena M; Schittulli F; Myles JD; Pater JL; Pritchard KI; Nomura Y; Anderson S; Bass G; Brown A; Bryant J; Costantino J; Dignam J; Fisher B; Redmond C; Wieand S; Wolmark N; Baum M; Jackson IM; Palmer MK; Ingle JN; Suman VJ; Bengtsson NO; Jonsson H; Larsson LG; Lythgoe JP; Swindell R; Kissin M; Erikstein B; Hannisdal E; Jacobsen AB; Varhaug JE; Erikstein B; Gundersen S; Hauer-Jensen M; Host H; Jacobsen AB; Nissen-Meyer R; Blamey RW; Mitchell AK; Morgan DAL; Robertson JFR; Di Palma M; Mathé G; Misset JL; Clark RM; Levine M; Morimoto K; Sawa K; Takatsuka Y; Crossley E; Harris A; Talbot D; Taylor M; Cocconi G; di Blasio B; Ivanov V; Semiglazov V; Brockschmidt J; Cooper MR; Ueo H; Falkson CI; A'Hern R; Ashley S; Powles TJ; Smith IE; Yarnold JR; Gazet JC; Cocoran N; Deshpande N; di Martino L; Douglas P; Hacking A; Host H; Lindtner A; Notter G; Bryant AJS; Ewing GH; Firth LA; Krushen-Kosloski JL; Nissen-Meyer R; Foster L; George WD; Stewart HJ; Stroner P; Malmström P; Möller TR; Rydén S; Tengrup I; Tennvall-Nittby L; Carstenssen J; Dufmats M; Hatschek T; Nordenskjöld B; Söderberg M; Carpenter JT; Albain K; Crowley J; Green S; Martino S; Osborne CK; Ravdin PM; Glas U; Johansson U; Rutqvist LE; Singnomklao T; Wallgren A; Castiglione M; Goldhirsch A; Maibach R; Senn HJ; Thürlimann B; Brenner H; Hercbergs A; Yoshimoto M; DeBoer G; Paterson AHG; Pritchard KI; Meakin JW; Panzarella T; Pritchard KI; Shan Y; Shao YF; Wang X; Zhao DB; Boreham J; Chen ZM; Pan HC; Peto R; Bahi J; Reid M; Spittle M; Deutsch GP; Senanayake F; Kwong DLW; Bianco AR; Carlomagno C; De Laurentiis M; De Placido S; Buzdar AU; Smith T; Bergh J; Holmberg L; Liljegren G; Nilsson J; Seifert M; Sevelda P; Zielinsky CC; Buchanan RB; Cross M; Royle GT; Dunn JA; Hills RK; Lee M; Morrison JM; Spooner D; Litton A; Chlebowski RT; Caffier H
Article: ANNALS OF ONCOLOGY. 2005;16(5):743-748
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF
Andersson J; Larsson L; Klaar S; Holmberg L; Nilsson J; Inganäs M; Carlsson G; Öhd J; Rudenstam CM; Gustavsson B; Bergh J
Article: BMC BIOINFORMATICS. 2005;6:80
Correlation test to assess low-level processing of high-density oligonucleotide microarray data
Ploner A; Miller LD; Hall P; Bergh J; Pawitan Y
Article: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(3):413-421
Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients
Sandström M; Lindman H; Nygren P; Lidbrink E; Bergh J; Karlsson MO
Article: BREAST CANCER RESEARCH. 2005;7(6):R953-R964
Gene expression profiling spares early breast cancer patients from adjuvant therapy:: derived and validated in two population-based cohorts
Pawitan Y; Bjöhle J; Amler L; Borg AL; Egyhazi S; Hall P; Han X; Holmberg L; Huang F; Klaar S; Liu ET; Miller L; Nordgren H; Ploner A; Sandelin K; Shaw PM; Smeds J; Skoog L; Wedrén S; Bergh J
Article: ANNALS OF ONCOLOGY. 2005;16:i73-i74
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Ewing's sarcoma of bone
Saeter G; Oliveira J; Bergh J
Article: ANNALS OF ONCOLOGY. 2005;16:i7-i9
ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer
Pestalozzi BC; Luporsi-Gely E; Jost LM; Bergh J
Article: ANNALS OF ONCOLOGY. 2005;16:i34-i36
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer
Kataja VV; Bergh J
Article: ANNALS OF ONCOLOGY. 2005;16:i10-i12
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC)
Kataja VV; Colleoni M; Bergh J
Article: ACTA ONCOLOGICA. 2005;44(1):41-49
Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events:: Analysis of loss of heterozygosity
Smeds J; Wärnberg F; Norberg T; Nordgren H; Holmberg L; Bergh J
Article: EUROPEAN JOURNAL OF CANCER. 2004;40(16):2417-2423
Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers
Linderholm B; Karlsson E; Klaar S; Lindahl T; Borg AL; Elmberger G; Bergh J
Article: RADIOTHERAPY AND ONCOLOGY. 2004;72(2):191-197
Quantitative assessment of skin erythema due to radiotherapy -: evaluation of different measurements
Wengström Y; Forsberg C; Näslund I; Bergh J
Article: STATISTICS IN MEDICINE. 2004;23(11):1767-1780
Gene expression profiling for prognosis using Cox regression
Pawitan Y; Bjöhle J; Wedren S; Humphreys K; Skoog L; Huang F; Amler L; Shaw P; Hall P; Bergh J
Article: CARCINOGENESIS. 2004;25(3):375-380
Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer
Lindahl T; Landberg G; Ahlgren J; Nordgren H; Norberg T; Klaar S; Holmberg L; Bergh J
Article: APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY. 2004;12(1):14-20
HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components
Andersson J; Linderholm B; Bergh J; Elmberger G
Article: CLINICAL BREAST CANCER. 2003;4(5):340-347
Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers.
Linderholm BK; Lindh B; Beckman L; Erlanson M; Edin K; Travelin B; Bergh J; Grankvist K; Henriksson R
Article: JOURNAL OF CLINICAL ONCOLOGY. 2003;21(19):3659-3664
Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group study 9401
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J
Article: ACTA RADIOLOGICA. 2003;44(5):472-484
Effect of granulocyte colony-stimulating factor (G-CSF)-supported chemotherapy on MR imaging of normal red bone marrow in breast cancer patients with focal bone metastases
Çiray I; Lindman H; Åström GKO; Wanders A; Bergh J; Ahlström HK
Article: CANCER NURSING. 2003;26(4):295-304
Attainment and importance of life values among patients with primary breast cancer
Lampic C; Thurfjell E; Bergh J; Carlsson M; Sjödén PO
Article: EUROPEAN JOURNAL OF CANCER. 2003;39(10):1370-1376
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer
Luoma ML; Hakamies-Blomqvist L; Sjöström J; Pluzanska A; Ottoson S; Mouridsen H; Bengtsson NO; Bergh J; Malmström P; Valvere V; Tennvall L; Blomqvist C
Article: THERAPEUTIC DRUG MONITORING. 2003;25(3):331-339
Doxorubicin-resistant, MRP1-expressing U-1285 cells are sensitive to idarubicin
Jönsson-Videsäter K; Andersson G; Bergh J; Paul C
Article: ACTA RADIOLOGICA. 2003;44(3):284-287
Early assessment of neoadjuvant chemotherapy by FEC-courses of locally advanced breast cancer using ^99mTc-MIBI
Wilczek B; von Schoultz E; Bergh J; Eriksson E; Larsson SA; Jacobsson H
Article: EUROPEAN JOURNAL OF CANCER. 2003;39(8):1105-1114
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients
Henningsson A; Sparreboom A; Sandström M; Freijs A; Larsson R; Bergh J; Nygren P; Karlsson MO
Article: LEUKEMIA AND LYMPHOMA. 2002;43(11):2179-2189
A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma
Amini RM; Berglund M; Rosenquist R; Von Heideman A; Lagercrantz S; Thunberg U; Bergh J; Sundström C; Glimelius B; Enblad G
Article: CLINICAL CANCER RESEARCH. 2002;8(9):2843-2850
A phase I study of CHS 828 in patients with solid tumor malignancy
Hovstadius P; Larsson R; Jonsson E; Skov T; Kissmeyer AM; Krasilnikoff K; Bergh J; Karlsson MO; Lönnebo A; Ahlgren J
Article: RESEARCH IN NURSING AND HEALTH. 2002;25(2):89-98
Life values before versus after a breast cancer diagnosis
Lampic C; Thurfjell E; Bergh J; Carlsson M; Sjödén PO
Article: EUROPEAN JOURNAL OF CANCER. 2002;38(4):535-542
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer
Sjöström J; Collan J; von Boguslawski K; Franssila K; Bengtsson NO; Mjaaland I; Malmström P; Ostenstad B; Wist E; Valvere V; Bergh J; Skiöld-Petterson D; Saksela E; Blomqvist C
Article: EUROPEAN JOURNAL OF SURGICAL ONCOLOGY. 2002;28(2):97-102
Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer
Ahlgren J; Holmberg L; Bergh J; Liljegren G
Article: MEDICAL ONCOLOGY. 2002;19(3):151-159
Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs
Berglund Å; Glimelius B; Bergh J; Brodin O; Fjällskog ML; Hagberg H; von Heideman A; Larsson R; Tholander B; de la Torre M; Åström G; Öberg K; Parö G; Nygren P
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2002;52(1):128-136
Pulmonary toxicity after radiotherapy in primary breast cancer patients:: Results from a randomized chemotherapy study
Hernberg M; Virkkunen P; Maasilta P; Keyriläinen J; Blomqvist C; Bergh J; Wiklund T
Article: EUROPEAN JOURNAL OF CANCER. 2002;38(1):64-69
Angiogenesis in invasive breast carcinoma - a prospective study of tumour heterogeneity
Ahlgren J; Risberg B; Villman K; Bergh J
Article: ACTA ONCOLOGICA. 2002;41(3):276-281
A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin®) on a named patient basis in Sweden
Andersson J; Linderholm B; Greim G; Lindh B; Lindman H; Tennvall J; Tennvall-Nittby L; Pettersson-Sköld D; Sverrisdottir A; Söderberg M; Klaar S; Bergh J
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. MONOGRAPHS. 2001;(30):103-108
Who should not receive adjuvant chemotherapy? International databases.
Bergh J; Holmquist M
Article: CANCER RESEARCH. 2001;61(22):8317-8321
Increased p53 mutation frequency during tumor progression -: Results from a breast cancer cohort
Norberg T; Klaar S; Kärf G; Nordgren H; Holmberg L; Bergh J
Article: JOURNAL OF ADVANCED NURSING. 2001;35(5):709-716
Timing of quality of life (QoL) assessments as a source of error in oncological trials
Hakamies-Blomqvist L; Luoma ML; Sjöström J; Pluzanska A; Sjödin M; Mouridsen H; Ostenstad B; Mjaaland I; Ottosson S; Bergh J; Malmström PO; Blomqvist C
Article: THE BMJ. 2001;322(7301):1538-1539
How apoptosis is regulated, and what goes wrong in cancer
Sjöström J; Bergh J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2001;67(3):235-244
Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients
Hall KS; Wiklund T; Erikstein B; Holte H; Kvalheim G; Sommer HH; Andersen A; Skovlund E; Bergh J; Hall C
Article: RADIOTHERAPY AND ONCOLOGY. 2001;59(3):257-265
Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis:: results from a double-blind, randomized study
Boström Å; Lindman H; Swartling C; Berne B; Bergh J
Article: CLINICAL CHEMISTRY. 2001;47(5):821-828
Enzymatic mutation detection method evaluated for detection of p53 mutations in cDNA from breast cancers
Norberg T; Klaar S; Lindqvist L; Lindahl T; Ahlgren J; Bergh J
Article: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 2001;10(5):495-499
Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ:: A population-based case-control study in Sweden
Wärnberg F; Bergh J; Zack M; Holmberg L
Article: ACTA ONCOLOGICA. 2001;40(2-3):135-154
The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types -: Summary and conclusions
Glimelius B; Bergh J; Brandt L; Brorsson B; Gunnars B; Hafström L; Haglund U; Högberg T; Janunger KG; Jönsson PE; Karlsson G; Kimby E; Lamnevik G; Nilsson S; Permert J; Ragnhammar P; Sörenson S; Nygren P
Article: CANCER RESEARCH. 2001;61(5):2256-2260
The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer
Linderholm BK; Lindahl T; Holmberg L; Klaar S; Lennerstrand J; Henriksson R; Bergh J
Article: EUROPEAN JOURNAL OF CANCER. 2001;37(4):463-469
Short- and long-term anxiety and depression in women recalled after breast cancer screening
Lampic C; Thurfjell E; Bergh J; Sjödén PO
Article: ACTA RADIOLOGICA. 2001;42(2):198-206
Early response of breast cancer bone metastases to chemotherapy evaluated with MR imaging
Çiray I; Lindman H; Åström KGO; Bergh J; Ahlström KH
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2001;93(2):128-133
Induction of p53 expression in skin by radiotherapy and UV radiation: A randomized study
Ponten F; Lindman H; Bostrom A; Berne B; Bergh J
Article: THE LANCET. 2000;356(9239):1384-1391
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer:: a randomised trial
Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
Article: ANNALS OF ONCOLOGY. 2000;11(10):1301-1307
Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients
von Heideman A; Sandström M; Csoka K; Tholander B; Larsson R; Bergh J; Nygren P
Article: ACTA RADIOLOGICA. 2000;41(5):435-440
Local breast cancer recurrence caused by mammographically guided punctures
Thurfjell MG; Jansson T; Nordgren H; Bergh J; Lindgren A; Thurfjell E
Article: CLINICAL CANCER RESEARCH. 2000;6(8):3103-3110
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer
Sjöström J; Blomqvist C; Heikkilä P; von Boguslawski K; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Article: CANCER GENE THERAPY. 2000;7(7):1069-1076
Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors
Dummer R; Bergh J; Karlsson Y; Horovitz JA; Mulder NH; Huinin DT; Burg G; Hofbauer G; Osanto S
Article: EUROPEAN JOURNAL OF CANCER. 2000;36(11):1411-1417
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil.: A multicentre randomised phase III trial by the Scandinavian Breast Group
Hakamies-Blomqvist L; Luoma ML; Sjöström J; Pluzanska A; Sjödin M; Mouridsen H; Ostenstad B; Mjaaland I; Ottosson-Lönn S; Bergh J; Malmström PO; Blomqvist C
Article: THE LANCET. 2000;355(9217):1757-1770
Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Article: ACTA RADIOLOGICA. 2000;41(2):178-182
Evaluation of new sclerotic bone metastases in breast cancer patients during treatment
Çiray I; Åström G; Andréasson I; Edekling T; Hansen J; Bergh J; Ahlström H
Article: LAKARTIDNINGEN. 2000;97(8):838
[Adjuvant therapy of breast cancer in the USA].
Bergh J
Article: BRITISH JOURNAL OF CANCER. 2000;82(4):777-781
Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer
Erselcan T; Kairemo KJA; Wiklund TA; Hernberg M; Blomqvist CP; Tenhunen M; Bergh J; Joensuu H
Article: JOURNAL OF TUMOR MARKER ONCOLOGY. 2000;15(3):177-186
Serum markers TPS, TPA and CA 15-3 as monitors of chemotherapy in patients with metastatic breast cancer
Lindman H; Jansson T; Arnberg H; Bergh J; Einarsson R
Article: DRUG METABOLISM AND DISPOSITION. 1999;27(10):1220-1223
Pharmacokinetic models for the saturable distribution of paclitaxel
Karlsson MO; Molnar V; Freijs A; Nygren P; Bergh J; Larsson R
Article: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 1999;8(9):769-774
Prognosis in women with a carcinoma in situ of the breast:: A population-based study in Sweden
Wärnberg F; Bergh J; Holmberg L
Article: EUROPEAN JOURNAL OF CANCER. 1999;35(8):1194-1201
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure:: a randomised phase III study with crossover on progression by the Scandinavian Breast Group
Sjöström J; Blomqvist C; Mouridsen H; Pluzanska A; Ottosson-Lönn S; Bengtsson NO; Ostenstad B; Mjaaland I; Palm-Sjövall M; Wist E; Valvere V; Anderson H; Bergh J
Article: JOURNAL OF CLINICAL ONCOLOGY. 1999;17(8):2326-2333
10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer:: A randomized trial
Liljegren G; Holmberg L; Bergh J; Lindgren A; Tabár L; Nordgren H; Adami HO
Article: CANCER GENETICS. 1999;111(2):105-110
Elucidation of the mechanism of homozygous deletion of 3p12∼13 in the U2020 cell line reveals the unexpected involvement of other chromosomes
Heppell-Parton AC; Nacheva E; Carter NP; Bergh J; Ogilvie D; Rabbitts PH
Article: EUROPEAN JOURNAL OF CANCER. 1999;35(5):714-720
Ductal carcinoma in situ of the breast from a population-defined cohort:: an evaluation of new histopathological classification systems
Wärnberg F; Nordgren H; Bergh J; Holmberg L
Article: METHODS IN MOLECULAR MEDICINE. 1999;28:179-199
Analysis of the p53 Status of Tumors : An Overview of Methods.
Bergh J
Article: ACTA ONCOLOGICA. 1999;38(5):567-572
Cross-comparison of two quality of life instruments used in a randomized study of combination chemotherapy in advanced breast cancer
Westman G; Ahlgren J; Jansson T; Bergh J
Article: ACTA ONCOLOGICA. 1999;38(2):239-245
FEC mobilized stem cells for high-dose therapy in breast cancer patients
Lindman H; Wiklund T; Holte H; Ljungman P; Blomqvist C; Kvalheim G; Bengtsson M; Höglund M; Wilking N; Bergh J
Article: LUNG CANCER. 1998;22(1):1-13
Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines;: lack of correlation with Bcl-2/Bax
Sirzén F; Zhivotovsky B; Nilsson A; Bergh J; Lewensohn R
Article: ONCOGENE. 1998;17(13):1723-1729
Homozygous deletions at 3p12 in breast and lung cancer
Sundaresan V; Chung G; Heppell-Parton A; Xiong J; Grundy C; Roberts I; James L; Cahn A; Bench A; Douglas J; Minna J; Sekido Y; Lerman M; Latif F; Bergh J; Li H; Lowe N; Ogilvie D; Rabbitts P
Article: THE LANCET. 1998;352(9132):930-942
Polychemotherapy for early breast cancer:: an overview of the randomised trials
Abe O; Abe R; Enomoto K; Kikuchi K; Koyama H; Nomura Y; Sakai K; Sugimachi K; Tominaga T; Uchino J; Yoshida M; Benraadt J; van de Velde AO; van Dongen JA; Vermorken JB; Giokas G; Lissaios B; Harvey VJ; Holdaway TM; Kay RG; Mason BH; Coates A; Forbes JF; Focan C; Lobelle JP; Gates GD; Powell J; Durand M; Mauriac L; Bartholomeus S; Piccart MJ; Gelman RS; Henderson IC; Shapiro CL; Hancock AK; Masood MB; Parker D; Price JJ; Jackson S; Ragaz J; Delozier T; Mace-Lesec'h J; Haybittle JL; Berry D; Broadwater G; Cirrincione C; Muss H; Norton L; Baum M; Houghton J; Riley D; Dent DM; Gudgeon CA; Hacking A; Gordon NH; Davis HL; Romestaing P; Lehingue Y; Owen JR; Meier P; Howell A; Ribeiro GC; Swindell R; Albano J; de Oliveira CF; Gervásio H; Gordilho J; Carstensen B; Palshof T; Johansen H; Korzeniowski S; Skolyszewski J; Portnoj SM; Andersen KW; Axelsson CK; Blichert-Toft M; Mouridsen HT; Overgaard M; Rose C; Corcoran N; Trampisch HJ; Comis RL; Davidson NE; Gray R; Robert N; Tormey DC; Wood W; Chetty U; Forrest P; Jack W; Rossbach J; Sylvester RJ; van de Velde CJH; Cunningham MP; Bonneterre J; Fumoleau P; Namer M; Bastert G; Rauschecker H; Sauer R; Sauerbrei W; Schauer A; Schumacher M; de Schryver A; Belfiglio M; Mari E; Nicolucci A; Scorpiglione N; Yosef HMA; McArdle CS; Smith DC; Lara PC; Boccardo F; Rubagotti A; Erazo A; Medina JY; Izuo M; Morishita Y; Bentley A; Doran Z; Fentiman IS; Hayward JL; Rubens RD; Kaufmann M; Jonat W; Scheurlen H; von Fournier D; Fountzilas G; Klafstrom P; Blomqvist C; Cuzick J; Margreiter R; Castiglione M; Cavilli F; Collins J; Forbes J; Gelber RD; Goldhirsch A; Lindtner J; Price KN; Rudenstam CM; Senn HJ; Bliss JM; Chilvers CED; Coombes RC; Marty M; Borovik R; Brufman G; Hayat H; Robinson E; Wigler N; Pannuti F; Takashima S; Yasutomi T; Sonoo H; Yamashita J; Ogawa M; Welvaart K; Hupperets PSGJ; Bonte J; Tengrup I; Tennvall-Nittby L; Martin P; Romain S; Ingle JN; Suman VJ; Buzdar AU; Smith T; Hakes T; Wittes R; de la Huerta R; Sainz MG; Bonadonna G; del Vecchio M; Valagussa P; Veronesi U; Dubois JB; Bianco AR; Lippman ME; Pierce LJ; Simon R; Steinberg SM; Myles JD; Pater JL; Pritchard KI; Anderson S; Brown A; Bryant J; Costantino J; Dignam J; Fisher B; Redmond C; Wieand S; Wolmark N; Jackson IM; Palmer MK; Bengtsson NO; Larsson LG; Lythgoe JP; Kissin M; Hannisdal E; Varhaug JE; Nissen-Meyer R; Blamey RW; Mitchell AK; Robertson JFR; Ueo H; Mathé G; Misset JL; Abu-Zahra HT; Clarke EA; McLaughlin JR; Clark RM; Levine M; Morimoto K; Sawa K; Takatsuka Y; Gundersen S; Hauer-Jensen M; Host H; Crossley E; Harris A; Beighton A; Clarke M; Collins R; Davies C; Evans V; Godwin J; Greaves E; Harwood C; Jackson D; James S; Lau E; Mead G; Naughten A; Peto R; Tooth A; Rambert P; Asselain B; Salmon RJ; Vilcoq JR; Arriagada R; Hill C; Laplanche A; Lê MG; Spielmann M; Cocconi G; di Blasio B; Catalano R; Creech RH; Brockschmidt J; Cooper MR; Andrysek O; Barkmanova J; Falkson CI; Abraham M; Klijn JGM; Treurniet-Donker AD; van Putten WLJ; Easton D; Powles TJ; Gazet JC; Semiglazov V; Deshpande N; di Martino L; Douglas P; Lindtner A; Notter G; Bryant AJS; Ewing GH; Krushen-Kosloski JL; George WD; Gould A; Stewart HJ; Stroner P; Möller TR; Rydén S; Carstensen J; Hatschek T; Söderberg M; Carpenter JT; Albain K; Crowley J; Green S; Martino S; Osborne CK; Ravdin PM; Rutqvist LE; Wallgren A; Holm LE; Thürlimann B; Brenner H; Hercbergs A; Yoshimoto M; DeBoer G; Paterson AHG; Meakin JW; Panzarella T; Naja A; Bahi J; Reid M; Spittle M; Senanayake F; Bergh J; Holmberg L; Sevelda P; Zielinsky CC; Gnant M; Jakesz R; Buchanan RB; Cross M; Dunn JA; Gillespie WM; Kelly K; Morrison JM; Litton A; Chlebowski RT; Bezwoda WR; Caffier H
Article: BONE MARROW TRANSPLANTATION. 1998;22(5):445-448
High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer
Ljungman P; Björkstrand B; Fornander T; Höglund M; Juliusson G; Lindman H; Malmström A; Rotstein S; Söderberg M; Wilking N; Villman K; Bergh J
Article: INTERNATIONAL JOURNAL OF CANCER. 1998;79(4):376-383
Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors
Norberg T; Lennerstrand J; Inganäs M; Bergh J
Article: THE LANCET. 1998;351(9114):1451-1467
Tamoxifen for early breast cancer: An overview of the randomised trials
Clarke M; Collins R; Davies C; Godwin J; Gray R; Peto R
Article: ANNALS OF ONCOLOGY. 1998;9(4):403-411
Dosage of adjuvant G-CSF (filgrastim) supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients
Bergh J; Wiklund T; Erikstein B; Fornander T; Bengtsson NO; Malmstrom P; Kellokumpu-Lehtinen P; Anker G; Bennmarker H; Wilking N
Article: ANTICANCER RESEARCH. 1998;18(2A):759-767
Production of a motility factor by a newly established lung adenocarcinoma cell line
Klominek J; Robért KH; Bergh J; Hjerpe A; Gahrton G; Sundqvist KG
Article: ANTICANCER RESEARCH. 1998;18(2A):695-699
Spontaneous and radiation-induced apoptosis in lung carcinoma cells with different intrinsic radiosensitivities
Sirzén F; Zhivotovsky B; Nilsson A; Bergh J; Lewensohn R
Article: CLINICAL CHEMISTRY. 1998;44(3):455-462
Assessment of sequence-based p53 gene analysis in human breast cancer:: messenger RNA in comparison with genomic DNA targets
Williams C; Norberg T; Ahmadian A; Pontén F; Bergh J; Inganäs M; Lundeberg J; Uhlén M
Article: SKELETAL RADIOLOGY. 1998;27(2):72-76
Skeletal metastases from breast cancer:: uptake of ¹⁸F-fluoride measured with positron emission tomography in correlation with CT
Petrén-Mallmin M; Andréasson I; Ljunggren Ö; Ahlström H; Bergh J; Antoni G; Långström B; Bergström M
Article: JOURNAL OF CLINICAL ONCOLOGY. 1998;16(2):462-469
Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
Sjögren S; Inganäs M; Lindgren A; Holmberg L; Bergh J
Article: PEPTIDES. 1998;19(2):231-239
Enhanced expression of neuropeptides in human breast cancer cell lines following irradiation
Aalto Y; Forsgren S; Kjorell U; Bergh J; Franzen L; Henriksson R
Article: RADIOTHERAPY AND ONCOLOGY. 1998;46(1):83-89
Radiotherapy of breast cancer after breast-conserving surgery:: an improved technique using mixed electron-photon beams with a multileaf collimator
Jansson T; Lindman H; Nygård K; Dahlgren CV; Montelius A; Öberg-Kreuger C; Asplund S; Bergh J
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 1998;63(1):11-25
A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression
Karlsson MO; Molnar V; Bergh J; Freijs A; Larsson R
Article: MUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS. 1997;395(2-3):127-138
Alkaline single-cell gel electrophoresis and human biomonitoring for genotoxicity: a pilot study on breast cancer patients undergoing chemotherapy including cyclophosphamide
Vaghef H; Nygren P; Edling C; Bergh J; Hellman B
Article: ANTICANCER RESEARCH. 1997;17(5A):3381-3386
Characterisation of the G1/S cell cycle checkpoint defect in lung carcinoma cells with different intrinsic radiosensitivities
Sirzen F; Heiden T; Nilsson A; Bergh J; Skog S; Lewensohn R
Article: ANNALS OF ONCOLOGY. 1997;8(8):757-763
The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial
Liljegren G; Karlsson G; Bergh J; Holmberg L
Article: ANNALS OF ONCOLOGY. 1997;8(3):235-241
Risk factors for local recurrence after conservative treatment in stage I breast cancer. Definition of a subgroup not requiring radiotherapy
Liljegren G; Lindgren A; Bergh J; Nordgren H; Tabar L; Holmberg L
Article: CANCER INVESTIGATION. 1997;15(3):204-211
The first clinical pilot study of roquinimex (Linomide(R)) in cancer patients with special focus on immunological effects
Bergh JCS; Totterman TH; Termander BC; Strandgarden KAMP; Gunnarsson POG; Nilsson BI
Article: ACTA ONCOLOGICA. 1997;36(2):171-174
Suramin in non-small cell lung cancer and advanced breast cancer - Two parallel phase II studies
Mirza MR; Jakobsen E; Pfeiffer P; LindebjergClasen B; Rose JC
Article: BRITISH JOURNAL OF CANCER. 1997;75(6):816-821
Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors
Davies SL; Bergh J; Harris AL; Hickson ID
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1996;88(21):1543-1549
Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
Rutqvist LE; Hatschek T; Ryden S; Bergh J; Bengtsson NO; Carstenssen J; Nordenskjold B; Wallgren A
Article: THE LANCET. 1996;348(9036):1189-1196
Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Article: ONCOLOGY REPORTS. 1996;3(6):1011-1016
Differential synthesis and binding of hyaluronan by human breast cancer cell lines: Relationship to hormone receptor status
Heldin P; delaTorre M; Ytterberg D; Bergh J
Article: MOLECULAR AND CELLULAR ENDOCRINOLOGY. 1996;121(2):143-151
Decreased growth rate and tumour formation of human anaplastic thyroid carcinoma cells transfected with a human thyrotropin receptor cDNA in NMRI nude mice treated with propylthiouracil
Gustavsson B; Hermansson A; Andersson AC; Grimelius L; Bergh J; Westermark B; Heldin NE
Article: JOURNAL OF CLINICAL ONCOLOGY. 1996;14(5):1581-1588
Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients
Sandstrom M; Freijs A; Larsson R; Nygren P; Fjallskog ML; Bergh J; Karlsson MO
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1996;88(3-4):173-182
The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
Sjogren S; Inganas M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
Article: ACTA ONCOLOGICA. 1996;35(4):473-478
Effects of interferons and tumour necrosis factor-alpha on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line
Pestana ES; Bjorklund G; Larsson R; Nygren P; Nilsson K; Bergh J
Article: JOURNAL OF CLINICAL ONCOLOGY. 1995;13(11):2745-2751
P53 STATUS PREDICTS SURVIVAL IN BREAST-CANCER PATIENTS TREATED WITH OR WITHOUT POSTOPERATIVE RADIOTHERAPY - A NOVEL HYPOTHESIS BASED ON CLINICAL FINDINGS
JANSSON T; INGANAS M; SJOGREN S; NORBERG T; LINDGREN A; HOLMBERG L; BERGH J
Article: ANTICANCER RESEARCH. 1995;15(6B):2791-2795
Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers
DelaTorre M; Heldin P; Bergh J
Article: NATURE MEDICINE. 1995;1(10):1029-1034
COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY
BERGH J; NORBERG T; SJOGREN S; LINDGREN A; HOLMBERG L
Article: CANCER RESEARCH. 1995;55(17):3908-3914
FUNCTIONAL HYALURONAN RECEPTORS ARE EXPRESSED ON A SQUAMOUS-CELL LUNG-CARCINOMA CELL-LINE BUT NOT ON OTHER LUNG-CARCINOMA CELL-LINES
TEDER P; BERGH J; HELDIN P
Article: LUNG CANCER. 1995;12(3):183-198
INCREASED RADIORESISTANCE OF AN IN-VITRO TRANSFORMED HUMAN SMALL-CELL LUNG-CANCER CELL-LINE
BRODIN O; ARNBERG H; BERGH J; NILSSON S
Article: JOURNAL OF CLINICAL ONCOLOGY. 1995;13(6):1470-1477
POSITRON EMISSION TOMOGRAPHY STUDIES IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST-CANCER - A METHOD FOR EARLY THERAPY EVALUATION
JANSSON T; WESTLIN JE; AHLSTROM H; LILJA A; LANGSTROM B; BERGH J
Article: HUMAN PATHOLOGY. 1995;26(2):180-185
EXPRESSION OF THE 85-KD MEMBRANE-PROTEIN IN PRIMARY HUMAN BREAST-CANCER - RELATIONSHIP TO HORMONE-RECEPTOR LEVELS, DNA-PLOIDY, AND TUMOR GRADE
DELATORRE M; NYGREN P; LARSSON R; LINDGREN A; TSURUO T; BERGH J
Visa fler

Alla övriga publikationer

Editorial comment: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 2024;103(4):775-778
Breast cancer during pregnancy-The oncologist's point of view
Matikas A; Bergh J
Other: ANNALS OF ONCOLOGY. 2024;35(2):159-182
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Loibl S; André F; Bachelot T; Barrios CH; Bergh J; Burstein HJ; Cardoso MJ; Carey LA; Dawood S; Del Mastro L; Denkert C; Fallenberg EM; Francis PA; Gamal-Eldin H; Gelmon K; Geyer CE; Gnant M; Guarneri V; Gupta S; Kim SB; Krug D; Martin M; Meattini I; Morrow M; Janni W; Paluch-Shimon S; Partridge A; Poortmans P; Pusztai L; Regan MM; Sparano J; Spanic T; Swain S; Tjulandin S; Toi M; Trapani D; Tutt A; Xu B; Curigliano G; Harbeck N; ESMO Guidelines Committee. Electronic address: cli
Editorial comment: ACTA ONCOLOGICA. 2024;63(1):3
Carl Blomqvist, Nordic network builder in oncology (1951-2023)
Hernberg M; Mattson J; Tenhunen M; Bergh J; Ahlgren J; Holmberg L; Sund M; Nilbert M
Review: EJNMMI RESEARCH. 2023;13(1):43
Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications
Altena R; Tzortzakakis A; Buren SA; Tran TA; Frejd FY; Bergh J; Axelsson R
Corrigendum: NATURE CANCER. 2022;3(5):649
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology (vol 3, pg 251, 2022)
Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Brana I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Balmana J; Apolone G; Caldas C; Bergh J; Ernberg I; Frohling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtio J
Review: CANCERS. 2022;14(8):1999
Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
Tzoras E; Zerdes I; Tsiknakis N; Manikis GC; Mezheyeuski A; Bergh J; Matikas A; Foukakis T
Review: FRONTIERS IN ONCOLOGY. 2022;12:999843
Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis
Zhu Y; Tzoras E; Matikas A; Bergh J; Valachis A; Zerdes I; Foukakis T
Review: CANCER TREATMENT REVIEWS. 2021;99:102257
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis
Boman C; Zerdes I; Martensson K; Bergh J; Foukakis T; Valachis A; Matikas A
Review: BREAST CANCER RESEARCH AND TREATMENT. 2021;189(1):15-23
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy
Polley M-YC; Dickler MN; Sinnwell J; Tenner K; de la Haba J; Loibl S; Goetz MP; Bergh J; Roberston J; Couch F; Ellis MJ; Martin M
Review: CARDIO-ONCOLOGY. 2021;7(1):20
Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer
Altena R; Hubbert L; Kiani NA; Wengstrom Y; Bergh J; Hedayati E
Review: ESMO OPEN. 2021;6(2):100074
The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
Delgado J; Vleminckx C; Sarac S; Sosa A; Bergh J; Giuliani R; Enzmann H; Pignatti F
Review: SEMINARS IN MUSCULOSKELETAL RADIOLOGY. 2020;24(06):692-709
Interventional Techniques for Bone and Musculoskeletal Soft Tissue Tumors: Current Practices and Future Directions-Part I. Ablation
Dalili D; Isaac A; Bazzocchi A; Astrom G; Bergh J; Lalam R; Weber M-A; Fritz J; Mansour R
Review: ESMO OPEN. 2020;5(6):e000798
European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma
Ali S; Camarero J; van Hennik P; Bolstad B; Gronvold MS; Syvertsen C; Strom BO; Okvist M; Josephson F; Keller-Stanislawski B; Zafiropoulos N; Pean E; Bergh J; Dias SDR; Pignatti F
Review: ESMO OPEN. 2020;5(4):e000856
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects
Moscetti L; Hennik P; Bolstad B; Camarero J; Josephson F; Melchiorri D; Gronvold MS; Sjoberg J; Botezatu M; Mulder J; Meulendijks D; Jimeno AT; Zafiropoulos N; Bergh J; Enzmann H; Pignatti F
Corrigendum: NATURE MEDICINE. 2020;26(7):1146
Author Correction: Caring for patients with cancer in the COVID-19 era.
van de Haar J; Hoes LR; Coles CE; Seamon K; Fröhling S; Jäger D; Valenza F; de Braud F; De Petris L; Bergh J; Ernberg I; Besse B; Barlesi F; Garralda E; Piris-Giménez A; Baumann M; Apolone G; Soria JC; Tabernero J; Caldas C; Voest EE
Review: ONCOLOGIST. 2020;25(2):e321-e327
The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Gronevik E; Muusse M; Hakonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Review: CLINICAL CANCER RESEARCH. 2019;25(18):5717-5726
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data
Matikas A; Zerdes I; Lovrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
Review: ANNALS OF ONCOLOGY. 2019;30(7):1044-1050
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
Matikas A; Foukakis T; Swain S; Bergh J
Review: CANCERS. 2019;11(5):E628-628
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chretien S; Zerdes I; Bergh J; Matikas A; Foukakis T
Editorial comment: JOURNAL OF INTERNAL MEDICINE. 2019;285(4):395-397
Minimally invasive tissue access as a tool for delivering personalized medicine - with focus on oncology
Matikas A; Foukakis T; Bergh J
Review: ESMO OPEN. 2019;4(5):e000570
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Tzogani K; Florez B; Markey G; Caleno M; Olimpieri OM; Melchiorri D; Hovgaard DJ; Sarac SB; Penttila K; Lapvetelainen T; Salmonson T; Bergh J; Gisselbrecht C; Pignatti F
Review: JOURNAL OF THORACIC ONCOLOGY. 2018;13(12):1818-1831
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
Blumenthal GM; Bunn PAJ; Chaft JE; McCoach CE; Perez EA; Scagliotti GV; Carbone DP; Aerts HJWL; Aisner DL; Bergh J; Berry DA; Jarkowski A; Botwood N; Cross DAE; Diehn M; Drezner NL; Doebele RC; Blakely CM; Eberhardt WEE; Felip E; Gianni L; Keller SP; Leavey PJ; Malik S; Pignatti F; Prowell TM; Redman MW; Rizvi NA; Rosell R; Rusch V; de Ruysscher D; Schwartz LH; Sridhara R; Stahel RA; Swisher S; Taube JM; Travis WD; Keegan P; Wiens JR; Wistuba II; Wynes MW; Hirsch FR; Kris MG
Letter: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(11):1280-1281
RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Matikas A; Foukakis T; Bergh J
Corrigendum: ANNALS OF ONCOLOGY. 2018;29(10):2153
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (vol 28, pg 1700, 2017)
Curigliano G; Burstein HJ; Winer EP; Gnant M; Dubsky P; Loibl S; Colleoni M; Regan MM; Piccart-Gebhart M; Senn H-J; Thurlimann B; Andre F; Baselga J; Bergh J; Bonnefoi H; Brucker SY; Cardoso F; Carey L; Ciruelos E; Cuzick J; Denkert C; Di Leo A; Ejlertsen B; Francis P; Galimberti V; Garber J; Gulluoglu B; Goodwin P; Harbeck N; Hayes DF; Huang C-S; Huober J; Khaled H; Jassem J; Jiang Z; Karlsson P; Morrow M; Orecchia R; Osborne KC; Pagani O; Partridge AH; Pritchard K; Ro J; Rutgers EJT; Sedlmayer F; Semiglazov V; Shao Z; Smith I; Toi M; Tutt A; Viale G; Watanabe T; Whelan TJ; Xu B
Review: ONCOGENE. 2018;37(34):4639-4661
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
Review: ONCOLOGIST. 2018;23(5):631-636
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
Tzogani K; van Hennik P; Walsh I; De Graeff P; Folin A; Sjoberg J; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
Published conference paper: BREAST CANCER RESEARCH AND TREATMENT. 2018;168(2):349-355
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
Matikas A; Margolin S; Hellstrom M; Johansson H; Bengtsson N-O; Karlsson L; Edlund P; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmstrom P; Villman K; Foukakis T; Bergh J
Letter: ANNALS OF ONCOLOGY. 2018;29(1):281-282
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.
Dubsky P; Curigliano G; Burstein HJ; Winer EP; Gnant M; Loibl S; Colleoni M; Regan MM; Piccart-Gebhart M; Senn H-J; Thurlimann B; Andre F; Baselga J; Bergh J; Bonnefoi H; Brucker SY; Cardoso F; Carey L; Ciruelos E; Cuzick J; Denkert C; Di Leo A; Ejlertsen B; Francis P; Galimberti V; Garber J; Gulluoglu B; Goodwin P; Harbeck N; Hayes DF; Huang C-S; Huober J; Khaled H; Jassem J; Jiang Z; Karlsson P; Morrow M; Orecchia R; Osborne KC; Pagani O; Partridge AH; Pritchard K; Ro J; Rutgers EJT; Sedlmayer F; Semiglazov V; Shao Z; Smith I; Toi M; Tutt A; Viale G; Watanabe T; Whelan TJ; Xu B
Letter: LAKARTIDNINGEN. 2017;114:EXYZ
Apropå! En välfungerande enhet.
Bergh J
Corrigendum: ANNALS OF ONCOLOGY. 2017;28(12):3111
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (vol 28, pg 16, 2016)
Cardoso F; Costa A; Senkus E; Aapro M; Andre F; Barrios CH; Bergh J; Bhattacharyya G; Biganzoli L; Cardoso MJ; Carey L; Corneliussen-James D; Curigliano G; Dieras V; El Saghir N; Eniu A; Fallowfield L; Fenech D; Francis P; Gelmon K; Gennari A; Harbeck N; Hudis C; Kaufman B; Krop I; Mayer M; Meijer H; Mertz S; Ohno S; Pagani O; Papadopoulos E; Peccatori F; Penault-Llorca F; Piccart MJ; Pierga JY; Rugo H; Shockney L; Sledge G; Swain S; Thomssen C; Tutt A; Vorobiof D; Xu B; Norton L; Winer E
Review: ONCOLOGIST. 2017;22(11):1339-1346
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
Tzogani K; Camarero Jimenez J; Garcia I; Sancho-Lopez A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
Review: ACTA ONCOLOGICA. 2017;56(9):1143-1151
Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts
Matikas A; Foukakis T; Bergh J
Review: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2017;114:91-101
Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine
Matikas A; Foukakis T; Bergh J
Corrigendum: BREAST. 2017;32:269-270
3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3) (vol 31, pg 244, 2017)
Cardoso F; Costa A; Senkus E; Aapro M; Andre F; Barrios CH; Bergh J; Bhattacharyya G; Biganzoli L; Cardoso MJ; Carey L; Corneliussen-James D; Curigliano G; Dieras V; El Saghir N; Eniu A; Fallowfield L; Fenech D; Francis P; Gelmon K; Gennari A; Harbeck N; Hudis C; Kaufman B; Krop I; Mayer M; Meijer H; Mertz S; Ohno S; Pagani O; Papadopoulos E; Peccatori F; Penault-Llorca F; Piccart MJ; Pierga JY; Rugo H; Shockney L; Sledge G; Swain S; Thomssen C; Tutt A; Vorobiof D; Xu B; Norton L; Winer E
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2017;35(2):254-255
Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology
Dittrich C; Kosty MP; Jezdic S; Pyle D; Berardi R; Bergh J; El-Saghir NS; Lotz J-P; Osterlund P; Pavlidis N; Purkalne G
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2017;35(1):121-122
Estradiol Level and Menopause Reply
Papakonstantinou A; Foukakis T; Rodriguez-Wallberg KA; Bergh J
Editorial comment: ANNALS OF ONCOLOGY. 2016;27(8):1378-1381
ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016
Dittrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El Saghir N; Lotz J-P; Osterlund P; Pavlidis N; Purkalne G
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2016;374(14):1386-1387
A 21-Gene Expression Assay in Breast Cancer
Foukakis T; Falato C; Bergh J
Editorial comment: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(9):895-897
Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies
Bergh J; Pritchard KI; Cameron D
Review: ANNALS OF ONCOLOGY. 2016;27(3):379-390
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
Hadji P; Coleman RE; Wilson C; Powles TJ; Clezardin P; Aapro M; Costa L; Body J-J; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert U-S; Conte P-F; Ejlertsen B; Bergh J; Kaufmann M; Holen I
Review: ESMO OPEN. 2016;1(5):e000097
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.
Dittrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El-Saghir N; Lotz J-P; Österlund P; Pavlidis N; Purkalne G; Awada A; Banerjee S; Bhatia S; Bogaerts J; Buckner J; Cardoso F; Casali P; Chu E; Close JL; Coiffier B; Connolly R; Coupland S; De Petris L; De Santis M; de Vries EGE; Dizon DS; Duff J; Duska LR; Eniu A; Ernstoff M; Felip E; Fey MF; Gilbert J; Girard N; Glaudemans AWJM; Gopalan PK; Grothey A; Hahn SM; Hanna D; Herold C; Herrstedt J; Homicsko K; Jones DV; Jost L; Keilholz U; Khan S; Kiss A; Köhne C-H; Kunstfeld R; Lenz H-J; Lichtman S; Licitra L; Lion T; Litière S; Liu L; Loehrer PJ; Markham MJ; Markman B; Mayerhoefer M; Meran JG; Michielin O; Moser EC; Mountzios G; Moynihan T; Nielsen T; Ohe Y; Öberg K; Palumbo A; Peccatori FA; Pfeilstöcker M; Raut C; Remick SC; Robson M; Rutkowski P; Salgado R; Schapira L; Schernhammer E; Schlumberger M; Schmoll H-J; Schnipper L; Sessa C; Shapiro CL; Steele J; Sternberg CN; Stiefel F; Strasser F; Stupp R; Sullivan R; Tabernero J; Travado L; Verheij M; Voest E; Vokes E; Von Roenn J; Weber JS; Wildiers H; Yarden Y
Editorial comment: ESMO OPEN. 2016;1(1):e000004
The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe.
Pavlidis N; Alba E; Berardi R; Bergh J; El Saghir N; Jassem J; Kosty M; Lopez R; Lotz J-P; Österlund P; Purkalne G; Dittrich C
Review: ESMO OPEN. 2016;1(6):e000127
The European Cancer Patient's Bill of Rights, update and implementation 2016.
Lawler M; Banks I; Law K; Albreht T; Armand J-P; Barbacid M; Barzach M; Bergh J; Cameron D; Conte P; de Braud F; de Gramont A; De Lorenzo F; Diehl V; Diler S; Erdem S; Geissler J; Gore-Booth J; Henning G; Højgaard L; Horgan D; Jassem J; Johnson P; Kaasa S; Kapitein P; Karjalainen S; Kelly J; Kienesberger A; La Vecchia C; Lacombe D; Lindahl T; Löwenberg B; Luzzatto L; Malby R; Mastris K; Meunier F; Murphy M; Naredi P; Nurse P; Oliver K; Pearce J; Pelouchov J; Piccart M; Pinedo B; Spurrier-Bernard G; Sullivan R; Tabernero J; Van de Velde C; van Herk B; Vedsted P; Waldmann A; Weller D; Wilking N; Wilson R; Yared W; Zielinski C; Zur Hausen H; Le Chevalier T; Johnston P; Selby P
Review: JOURNAL OF INTERNAL MEDICINE. 2015;278(6):545-570
The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer
Tobin NP; Foukakis T; De Petris L; Bergh J
Letter: LAKARTIDNINGEN. 2015;112:DF43
[Sweden does not prioritize important cancer drugs].
Bergh J
Corrigendum: MOLECULAR ONCOLOGY. 2014;8(6):1159
Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients (vol 8, pg 741, 2014)
Tobin NP; Lindstrom LS; Carlson JW; Bjohle J; Bergh J; Wennmalm K
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(1):84-85
Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors
Foukakis T; Lovrot J; Bergh J
Review: ARCHIVES OF GYNECOLOGY AND OBSTETRICS. 2013;288(6):1203-1212
Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades
Kaufmann M; von Minckwitz G; Bergh J; Conte P-F; Darby S; Eiermann W; Howell A; Kiechle M; Mauri D; Senn H-J; Viale G; Loibl S
Editorial comment: JOURNAL OF INTERNAL MEDICINE. 2013;274(2):102-104
Breast cancer biology and the future of tailored therapies
Bergh J; Hall P; Ostman A; Toftgard R
Review: BREAST. 2012;21(1):20-26
Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design
Eiermann W; Bergh J; Cardoso F; Conte P; Crown J; Curtin NJ; Gligorov J; Gusterson B; Joensuu H; Linderholm BK; Martin M; Penault-Llorca F; Pestalozzi BC; Razis E; Sotiriou C; Tjulandin S; Viale G
Meeting abstract: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2011;81(2):S62
RSI: A Novel Biomarker Predicts RT Therapeutic Benefit in Breast Cancer
Torres-Roca JF; Fulp WJ; Pawitan Y; Kamath V; Lee J; Harris EE; Bergh J; Eschrich S
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2011;47:S337-S338
Clinically Used Breast Cancer Markers are Heterogeneous Throughout Tumour Progression
Lindstrom LS; Karlsso E; Wilking U; Bergh J
Corrigendum: THE LANCET ONCOLOGY. 2011;12(2):116
Retraction-validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial (Retraction of vol 8, pg 1071, 2007)
Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; Andre S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
Editorial comment: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(30):4548-4550
Insights Into the Place of Fulvestrant for the Treatment of Advanced Endocrine Responsive Breast Cancer
Howell A; Bergh J
Review: JOURNAL OF THE NATIONAL CANCER INSTITUTE. MONOGRAPHS. 2010;2010(41):162-177
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.
Early Breast Cancer Trialists' Collaborative Group; Correa C; McGale P; Taylor C; Wang Y; Clarke M; Davies C; Peto R; Bijker N; Solin L; Darby S
Meeting abstract: EJC SUPPLEMENTS. 2010;8(3):217
Uptake of trastuzumab (T) in selected European countries during the first 9 years after market introduction
Wilking U; Bergh J; Jonsson B; Kasteng F; Wilking N
Meeting abstract: EJC SUPPLEMENTS. 2010;8(3):208
Breast cancer care and outcomes in 18 countries in Europe, Asia, and Latin America
Kasteng F; Bergh J; Jonsson B; Kossler I; Martin M; Reed L; Widdershoven G; Wilking N
Meeting abstract: EJC SUPPLEMENTS. 2010;8(3):124
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Iggo R; Farmer P; Wirapati P; Anderle P; Delorenzi M; Bogaerts J; Piccart M; Cameron D; Bergh J; Bonnefoi H
Meeting abstract: EJC SUPPLEMENTS. 2010;8(3):55
Similar outcome in a randomized phase III trial comparing docetaxel versus vinorelbine both combined with trastuzumab as first line treatment for metastatic or locally advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer
Andersson M; Lidbrink E; Wist E; Enevoldsen K; Jensen AB; Sorensen PG; Bjerre K; Moller S; Bergh J; Langkjer ST
Meeting abstract: EJC SUPPLEMENTS. 2009;7(2):261
Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab
Cardoso F; Gianni L; Jerusalem G; Fasolo A; Bergh J; Dieras V; Manlius C; Mukhopadhyay P; Massacesi C; Sahmoud T
Letter: NATURE MEDICINE. 2009;15(3):237-238
Stromal signature identifies basal breast cancers
Wennmalm K; Ostman A; Bergh J
Corrigendum: NATURE MEDICINE. 2009;15(2):220
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer (vol 15, pg 68, 2009)
Farmer P; Bonnefoi H; Anderle P; Cameron D; Wirapati P; Becette V; Andre S; Piccart M; Campone M; Brain E; MacGrogan G; Petit T; Jassem J; Bibeau F; Blot E; Bogaerts J; Aguet M; Bergh J; Iggo R; Delorenzi M
Editorial comment: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(1):2-5
Quo Vadis With Targeted Drugs in the 21st Century?
Bergh J
Corrigendum: BREAST. 2008;17(3):319
"How to treat male breast cancer" (vol 16S2, pg S147, 2007)
Czene K; Bergqvist J; Hall P; Bergh J
Meeting abstract: EJC SUPPLEMENTS. 2008;6(7):116-117
A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
Margolin S; Carlsson L; Hellstrom M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmstrom P; Pettersson DS; Bergh J
Meeting abstract: EJC SUPPLEMENTS. 2008;6(7):51
Coping with expensive drugs around the world
Wilking N; Bergh J; Wilking U; Jonsson B
Editorial comment: ACTA ONCOLOGICA. 2008;47(2):316-318
Radiological assessment of tumour response to anti-cancer drugs:: Time to reappraise
Nygren P; Blomqvist L; Bergh J; Astrom G
Published conference paper: BREAST. 2007;16:S147-S154
How to treat male breast cancer
Kamila C; Jenny B; Per H; Jonas B
Published conference paper: JOURNAL OF CLINICAL ONCOLOGY. 2007;25(25):3859-3865
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JGM; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
Meeting abstract: EJC SUPPLEMENTS. 2007;5(4):50-51
The effects and interaction by multimodal therapies, radiation, cytostatics and trastuzumab, on cardiac toxicity
Bergh J
Meeting abstract: EJC SUPPLEMENTS. 2007;5(6):13
Clinical validation of in vitro drug sensitivity microarray data: regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01)
Bonnefoi H; Potti A; Mauriac L; Tubiana-Hulin M; Campone M; Cameron D; Bergh J; Delorenzi M; Nevins JR; Iggo R
Published conference paper: CLINICAL CANCER RESEARCH. 2007;13(11):3207-3214
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
Desmedt C; Piette F; Loi S; Wang Y; d'assignies MS; Bergh J; Lidereau R; Ellis P; Harris AL; Klijn JGM; Foekens JA; Cardoso F; Piccart MJ; Buyse M; Sotiriou C
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2007;356(18):1887-1888
A gene signature in breast cancer
Wennmalm K; Miller LD; Bergh J
Meeting abstract: BREAST. 2007;16:S10-S11
How to treat male breast cancer
Bergqvist J; Czene K; Hall P; Bergh J
Published conference paper: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2006;58(2):143-156
Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients
Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
Corrigendum: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2005;102(49):17882
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival (vol 102, pg 13550, 2005)
Miller LD; Smeds J; George J; Vega VB; Vergara L; Ploner A; Pawitan Y; Hall P; Klaar S; Liu ET; Bergh J
Published conference paper: BREAST. 2005;14(6):564-569
Adjuvant chemotherapy for breast cancer - "one fits all"?
Bergh J
Review: ANNALS OF ONCOLOGY. 2005;16(10):1569-1583
Meeting highlights:: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
Goldhirsch A; Glick JH; Gelber RD; Coates AS; Thürlimann B; Senn H; Albain KS; Bergh J; Castiglione-Gertsch M; Coates AS; Costa A; Cuzick J; Davidson N; Forbes JF; Gelber RD; Goss P; Harris J; Glick JH; Goldhirsch A; Howell A; Ingle JN; Jakesz R; Jassem J; Kaufmann M; Martin M; Mauriac L; Morrow M; Mouridsen HT; Namer M; Piccart-Gebhart MJ; Possinger K; Pritchard K; Rutgers EJT; Thürlimann B; Viale G; Wallgren A; Wood WC
Meeting abstract: BREAST CANCER RESEARCH. 2005;7:S56-S57
Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
Drageset V; Nesland JM; Erikstein B; Skovlund E; Sommer H; Anker G; Wist E; Lundgren S; Bergh J; Kvalheim G
Meeting abstract: BREAST CANCER RESEARCH. 2005;7:S54
Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients
Olivier M; Langerod A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Borresen-Dale AL
Meeting abstract: BREAST CANCER RESEARCH. 2005;7:S48
Gene expression profiling in breast cancer challenges the existence of intermediate histological grade
Sotiriou C; Wirapati P; Loi S; Harris A; Bergh J; Smeds J; Praz V; Farmer P; Halbe-Kains B; Lallemand F; Buyse M; Piccart M; Delorenzi M
Meeting abstract: BREAST CANCER RESEARCH. 2005;7:p2.11-S31
Identification of molecular apocrine breast tumours by microarray analysis
Farmer P; Bonnefoi H; Becette V; Tubiana-Hulin M; Fumoleau P; Larsimont D; MacGrogan G; Bergh J; Cameron D; Goldstein D; Duss S; Nicoulaz AL; Fiche M; Brisken C; Delorenzi M; Iggo R
Published conference paper: ANNALS OF ONCOLOGY. 2005;16:ii195-ii202
Gene profile and response to treatment
Smeds J; Miller LD; Bjöhle J; Hall P; Klaar S; Liu ET; Pawitan Y; Ploner A; Bergh J
Letter: CLINICAL CHEMISTRY. 2004;50(5):975-976
Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies
Egyházi S; Bjöhle J; Skoog L; Huang F; Borg AL; Stolt MF; Hägerström T; Ringborg U; Bergh J
Editorial comment: ACTA ONCOLOGICA. 2004;43(1):5-7
Weekly taxanes - A leap forward or a minute progress?
Linderholm B; Bergh J
Published conference paper: BREAST. 2003;12(6):529-537
Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy - cytotoxicity, duration and responsiveness
Bergh J
Editorial comment: THE LANCET. 2003;362(9379):183-184
Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen?
Bergh J
Editorial comment: ANNALS OF ONCOLOGY. 2002;13(3):343-344
Is pharmacokinetically guided chemotherapy dosage a better way forward?
Bergh J
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2002;38:S109
The proliferation marker MIB1 correlates less well with S-phase fraction but rather with mutant p53, poor Elston grade, high cyclin E expression and worse prognosis in human primary breast cancer
Linderholm B; Lindahl T; Folin A; Borg AL; Klaar S; Ahlgren J; Holmberg L; Lindgren A; Bergh J
Review: ACTA ONCOLOGICA. 2001;40(2-3):253-281
A systematic overview of chemotherapy effects in breast cancer
Bergh J; Jönsson PE; Glimelius B; Nygren P
Published conference paper: ANTICANCER RESEARCH. 2000;20(6D):5089-5093
Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients
Einarsson R; Lindman H; Bergh J
Letter: THE LANCET. 2000;356(9229):595-596
High-dose chemotherapy for breast cancer - Reply
Bergh J
Editorial comment: THE LANCET. 2000;355(9208):944-945
Where next with stem-cell-supported high-dose therapy for breast cancer?
Bergh J
Published conference paper: ACTA ONCOLOGICA. 2000;39(3):319-326
Can axillary dissection be avoided by improved molecular biological diagnosis?
Lindahl T; Engel G; Ahlgren J; Klaar S; Bjöhle J; Lindman H; Andersson J; von Schoultz E; Bergh J
Corrigendum: THE LANCET. 2000;356(9248):2196
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial (vol 356, pg 1384, 2000)
Bergh J
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1999;35:S355
A high correlation between mutant p53 and increased expression of vascular endothelial growth factor (VEGF), combining those markers indicates poor effect by adjuvant tamoxifen in ER positive patients
Linderholm B; Lindahl T; Lennerstrand J; Henriksson R; Bergh J
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1999;35:s83
Adjuvant anthracycline in breast cancer.: Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin
Mouridsen HT; Andersen J; Andersson M; Dombernowsky P; Ejlertsen B; Rose C; Sorensen PG; Sandberg E; Andersen KW; Jensen MB; Bengtson NO; Bergh J; Nordenskjöld B
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1999;35:S219
High dose chemotherapy in the adjuvant setting for high risk breast cancer patients - Results from a randomized study
Bergh J
Published conference paper: ENDOCRINE-RELATED CANCER. 1999;6(1):51-59
Clinical studies of p53 in treatment and benefit of breast cancer patients
Bergh J
Published conference paper: ACTA ONCOLOGICA. 1999;38:37-46
Is there a role for intensive therapy in breast cancer?
Bergh J
Published conference paper: ACTA ONCOLOGICA. 1999;38(7):955-959
Radiation recall -: Another call with tamoxifen
Boström Å; Sjölin-Forsberg G; Wilking N; Bergh J
Published conference paper: CANCER. 1998;83(5):936-947
Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide -: Prognostic and therapeutic implications
Karlsson YA; Malmström PO; Hatschek T; Fornander TG; Söderberg M; Bengtsson NO; Jansson TE; Sjöberg SM; Bergh JC
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1998;34:s34
Multimodality therapy of 128 patients with locally advanced breast cancer in the era of mammography screening using standard FEC-prognostic and therapeutic implications
Karlsson Y; Malmström P; Hatschek T; Fornander T; Söderberg M; Bengtsson NO; Jansson T; Sjöberg S; Bergh J
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1998;34:S31
Sector resection with or without postoperative radiotherapy for stage I breast cancer. Long term results and definition of a subgroup not requiring radiotherapy
Liljegren G; Holmberg L; Adami HO; Bergh J
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1998;34:S8
Tailored therapy to equal toxicity: Is it possible?
Bergh J
Review: RECENT RESULTS IN CANCER RESEARCH. 1998;152:328-340
Tailored chemotherapy to equal toxicity: is it possible?
Bergh J
Editorial comment: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1997;89(9):605-607
Time for integration of predictive factors for selection of breast cancer patients who need postoperative radiation therapy?
Bergh J
Editorial comment: ANNALS OF ONCOLOGY. 1997;8(2):109-110
Dose intensity in patients with metastatic breast cancer - Time for novel thoughts?
Bergh J
Letter: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1996;88(20):1500
The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry - Response
Nordgren H; Lindgren A; Bergh J
Published conference paper: ACTA ONCOLOGICA. 1996;35(5):96-102
Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53
Norberg T; Jansson T; Sjogren S; Martensson C; Andreasson I; Fjallskog ML; Lindman H; Nordgren H; Lindgren A; Holmberg L; Bergh J
Published conference paper: ACTA ONCOLOGICA. 1996;35(5):75
Second-line endocrine treatment of advanced breast cancer - A randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide
Hultborn R; JohanssonTerje I; Bergh J; Glas U; Hallsten L; Hatschek T; Holmberg E; Idestrom K; Norberg B; Ranstam J; Soderberg M; Wallgren UB
Letter: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1995;87(9):688-689
RE - SECTOR RESECTION WITH OR WITHOUT POSTOPERATIVE RADIOTHERAPY FOR STAGE-I BREAST-CANCER - 5-YEAR RESULTS OF A RANDOMIZED TRIAL - RESPONSE
LILJEGREN G; HOLMBERG L; BERGH J
Other: BRITISH JOURNAL OF CANCER. 1995;71(3):478-481
CYTOTOXIC ACTIVITY OF TAXOL IN PRIMARY CULTURES OF TUMOR-CELLS FROM PATIENTS IS PARTLY MEDIATED BY CREMOPHOR EL
NYGREN P; CSOKA K; JONSSON B; FRIDBORG H; BERGH J; HAGBERG H; GLIMELIUS B; BRODIN O; THOLANDER B; KREUGER A; LONNERHOLM G; JAKOBSSON A; OLSEN L; KRISTENSEN J; LARSSON R
Published conference paper: ACTA ONCOLOGICA. 1995;34(5):669-674
HIGH-DOSE THERAPY WITH AUTOLOGOUS BONE-MARROW STEM-CELL SUPPORT IN PRIMARY AND METASTATIC HUMAN BREAST-CANCER
BERGH J
Visa fler

Anställningar

Professor, Senior, Onkologi-Patologi, Karolinska Institutet, 2025-2025
Professor, Onkologi-Patologi, Karolinska Institutet, 2000-2025

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Nyheter från KI

Kalenderhändelser från KI